Additional file 3: Outcome data for included studies

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Albert et al, 2001 a	Pravastatin 40 mg/d (n=1014) Placebo (n=999)	mg/dL	Pravastatin: Baseline 231 ± 34 24 wks -38.3 no SD change -16% no SD Placebo: Baseline 231 ± 32 24 wks +1.1 no SD change +1.2% no SD	Pravastatin: Baseline 143 ± 26 24 wks -32 no SD change -22% no SD Placebo: Baseline 143 ±26 24 wks +0.6 no SD change +1.8% no SD	Pravastatin: Baseline 40 ± 10 24 wks +2.3 no SD change +7% no SD Placebo: Baseline 40 — 11 24 wks +0.8 no SD change +2% no SD	Pravastatin: MEDIAN Baseline 160 (IQR 114-233) 24 wks -18 no SD change -13% no SD Placebo: MEDIAN Baseline 161 (IQR 116-231) 24 wks -3.0 no SD change -2% no SD	
Arntz et al, 1999	Pravastatin 20 mg once daily (n= 58) Bezafibrate 400 mg daily (n= 38) Dose doubled if LDL was >190 mg/dL after 6 wks	mg/dL	Pravastatin: Baseline 364 ± 75 12 wks 281 ± 61 absolute change -83 Bezafibrate: Baseline 363 ± 91 12 wks 325 ± 73 absolute change -38	Pravastatin: Baseline 288 ± 81 12 wks 206 ± 64 absolute change -82 Bezafibrate: Baseline 284 ± 88 12 wks 242 ± 70 absolute change -42	Pravastatin: Baseline 46 ± 17 12 wks 50 ≠ 18 absolute change +4 Bezafibrate: Baseline 52 ± 18 12 wks 58 ≠ 21 absolute change +6	Pravastatin: Baseline 168 ± 83 12 wks 148 ± 80 absolute change -20 Bezafibrate: Baseline 173 ± 91 12 wks 121 ± 83 absolute change -52	Significant change from baseline at 12 wks with pravastatin for triglycerides & HDL ($p<0.05$) and LDL cholesterol ($p<0.01$). Significant change from baseline at 12 wks with bezafivrate for HDL ($p<0.05$) and triglycerides & LDL cholesterol ($p<0.01$)

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Bak et al, 1998	Pravastatin 20 mg + Step 1 diet: (n= 54) Pravastatin 20 mg + Step 2 diet: (n= 55) Placebo + Step 1diet (n= 53) Placebo + Step 2 diet (n= 53)	mmol/L	Pravastatin Step 1: Baseline 7.28 ± 0.58; 6 mths no data; change -19.4% ± SEM 1.6 Pravastatin Step 2: Baseline 7.20 ±0.61; 6 mths no data; change -20.7% ± SEM 1.7 Placebo Step 1: Baseline 7.37 ± 0.67; 6 mths no data; change +0.5% ± SEM 1.3 Placebo Step 1: Baseline 7.37 ± 0.62; 6 mths no data; change -6.3 ± SEM 1.4	Pravastatin Step 1: Baseline 5.15 ± 0.74; 6 mths no data; change -26.7% ± SEM 2.1 Pravastatin Step 2: Baseline 5.06 ± 0.68; 6 mths no data; change -28.8% ± SEM 2.4 Placebo Step 1: Baseline 5.29 ± 0.59; 6 mths no data; change +1.8% ± SEM 1.4 Placebo Step 1: Baseline 5.34 ± 0.62; 6 mths no data; change -8.6% ± SEM 2.0	Pravastatin Step 1: Baseline 1.1 ± 0.3; 6 mths no data; change +14.1% ± SEM 4.9 Pravastatin Step 2: Baseline 1.1 ± 0.2; 6 mths no data; change +10.6% ± SEM 2.6 Placebo Step 1: Baseline 1.1 ± 0.2; 6 mths no data; change +2.9% ± SEM 2.6 Placebo Step 1: Baseline 1.1 ± 0.2; 6 mths no data; change +5.8% ± 3.6	Pravastatin Step 1: Baseline 2.19 ± 1.1; 6 mths no data; change -8.2% ± SEM 5.8 Pravastatin Step 2: Baseline 2.2 ± 0.89; 6 mths no data; change -6.6% ± SEM 5.4 Placebo Step 1: Baseline 2.06 ± 1.0; 6 mths no data; change +7.8% ± SEM 7.9 Placebo Step 1: Baseline 2.08 ± 0.73; 6 mths no data; change -0.02% ± SEM 5.6	Significant reductions in total cholesterol with pravastatin
Beigel et al, 1993	Pravastatin 20 mg (evening) (n= 38) Placebo (n=39) Dose doubled in 6 pts after 13 wks because total cholesterol >200 mg/dL & reduction from baseline was <15%	mg/dL	Pravastatin: Baseline 262 ± 4.0; 26 wks 214 ± 5.0; change no data Placebo: Baseline 267 ± 3.0; 26 wks 268 ± 4.0; change no data	Pravastatin: Baseline 186 ± 4.0; 26 wks 191 ± 5.0; change no data Placebo: Baseline 191 ± 4.0; 26 wks 144 ± 4.0; change no data	Pravastatin: Baseline 37.9 ± 1.4; 26 wks 42..8 ± 1.7; change no data Placebo: Baseline 39.5 ± 1.6; 26 wks 38.9 ± 1.6; change no data	Pravastatin: Baseline 165 ± 12; 26 wks 115 ± 11; change no data Placebo: Baseline 158 ± 11; 26 wks 162 ± 11; change no data	Pravastatin: Significant reduction in total cholesterol from baseline & better than placebo (p<0.001) for total cholesterol, LDL, HDl and trigycerides.

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Bertolini et al, 1997	Atorvastatin 10 mg (n= 227) Pravastatin 20 mg (n= 78) Once in the evening Initial dose was doubled at wk 16 if LDL goals not met at wk 4 & 10 By wk 52 daily dose taken: Atorv 10 mg 76% Atorv20 mg 24% Prav 20 mg 36% Prav 40 mg 64%	mmol/L	Atorvastatin: Baseline 7.16 ± SE 0.05 1 yr no data Change -25% ± SE 0.8 Pravastatin: Baseline 7.19 ± SE 0.07 1 yr no data Change -16% ± SE 1.2	Atorvastatin: Baseline 5.02 ± 0.04 1 yr no data Change -35% ± SE 1.0 Pravastatin: Baseline 5.07 ± 0.06 1 yr no data Change -23% ± SE 1.6	Atorvastatin: Baseline 1.37 ± 0.03 1 yr no data Change +7% ± SE 1.0 Pravastatin: Baseline 1.27 ± SE 0.03 1 yr no data Change +10% ± SE 1.5	Atorvastatin: Baseline 1.65 ± SE 0.05 1 yr no data Change -14% ± SE 2.0 Pravastatin: Baseline 1.80 ± SE 0.09 1 yr no data Change -3% ± SE 3.1	Atorvastatin was significantly better at reducing total cholesterol, LDL & triglycerides than pravastatin. No significant difference for HDL
Bestehorn et al, 1997	Simvastatin 20 mg (n= 129) Placebo (n= 125) Once daily Dose doubled after 6 wks if LDL >90 mg/dL. After 12 wks an ion exchnage resin was added if LDL> 120 mg/dL with simvastatin (>250 mg/dL with placebo) Mean dose/day taken	mg/dL	Simvastatin: Baseline 240 ± SE 3.8 30 mths no data change -28.5% Placebo: Baseline 243 ± SE 3.5 No further data	Simvastatin: Baseline 165 ± SE 3.3 30 mths change -35% Placebo: Baseline 167 ± SE 3.2 30 mths no data change no change	Simvastatin: Baseline 44 ± SE 0.9 30 mths no data change +6.1% Placebo: Baseline 44 ± SE 0.9 No further data	Triglycerides fell by 28% with simvastatin. No further data provided.	

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Betteridge et al,1999	Treatments given orally, once daily in the evening Cerivastatin 0.025 mg (n=193) Cerivastatin 0.05 mg (n= 187) Cerivastatin 0.1 mg (n= 190) Cerivastatin 0.2 mg (n= 191) Placebo (n= 187) Simvastatin 20 mg (n= 183)	mg/dL	Cerivastatin 0.025 mg: Baseline 298 no SD 12 wks no data change -8.8% ± SE 0.7 Cerivastatin 0.5 mg: Baseline 294 no SD 12 wks no data change -11.9% ± SE 0.7 Cerivastatin 0.1 mg: Baseline 292 no SD 12 wks no data change -17.8% ± SE 0.7 Cerivastatin 0.2 mg: Baseline 295 no SD 12 wks no data change -21.8% ± SE 0.7 Simvastatin 20 mg: Baseline 298 no SD 12 wks no data change -28.2% ± SE 0.7 Placebo: Baseline 300 no SD 12 wks no data change -0.5% ± SE 0.7	Cerivastatin 0.025 mg: Baseline 218 no SD 12 wks no data change -11.5% ± SE 0.9 Cerivastatin 0.5 mg: Baseline 215 no SD 12 wks no data change -15.5% ± SE 0.9 Cerivastatin 0.1 mg: Baseline 212 no SD 12 wks no data change -23.6% ± SE 0.9 Cerivastatin 0.2 mg: Baseline 216 no SD 12 wks no data change -29.1% ± SE 0.9 Simvastatin 20 mg: Baseline 218 no SD 12 wks no data change -38.3% ± SE 0.9 Placebo: Baseline 218 no SD 12 wks no data change -0.3% ± SE 0.9	Cerivastatin 0.025 mg: Baseline 52 no SD 12 wks no data change +0.2% ± SE 1.0 Cerivastatin 0.5 mg: Baseline 53 no SD 12 wks no data change +1.4% ± SE 0.9 Cerivastatin 0.1 mg: Baseline 51 no SD 12 wks no data change +3.7% ± SE 1.0 Cerivastatin 0.2 mg: Baseline 52 no SD 12 wks no data change +3.2 ± SE 1.0 Simvastatin 20 mg: Baseline 53 no SD 12 wks no data change +5.2% ± SE 1.0 Placebo: Baseline 54 no SD 12 wks no data change -1.1% ± SE 1.0	Cerivastatin 0.025 mg: Baseline 141 no SD 12 wks no data change -0.2% ± SE 2.0 Cerivastatin 0.5 mg: Baseline 136 no SD 12 wks no data change -5.7% ± SE 2.0 Cerivastatin 0.1 mg: Baseline 143 no SD 12 wks no data change -10.4% ± SE 2.0 Cerivastatin 0.2 mg: Baseline 140 no SD 12 wks no data change -10.9% ± SE 2.0 Simvastatin 20 mg: Baseline 137 no SD 12 wks no data change -12.8% ± SE 2.0 Placebo: Baseline 140 no SD 12 wks no data change +5.7% ± SE 2.0	
Bevilacqua et al, 1997	Fluvastatin 40 mg (n= 25) Placebo (n= 23) Once daily	mg/dL	Fluvastatin: Baseline 246 ± 48 20 wks 216 ± 44 change no data Placebo: Baseline 245 ± 59 20 wks 271 ± 53 change no data	Fluvastatin: Baseline 173 ± 40 20 wks 134 ± 44 change no data Placebo: Baseline 165 ± 49 20 wks 187 ± 56 change no data	Fluvastatin: Baseline 48 ± 14 20 wks 57 ± 14 change no data Placebo: Baseline 45 ± 12 20 wks 51 ± 19 change no data	Fluvastatin: Baseline 117 ± 42 20 wks 124 ± 65 change no data Placebo: Baseline 133 ± 64 20 wks 181 ± 101 change no data	Fluvastatin was significantly better at reducing total cholesterol, LDL ($p<0.01$), HDL and triglycerides ($p<0.05$) than placebo

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Blankenhorn et al, 1993	Lovastatin 80 mg (n= 123) 40 mg given twice daily Placebo (n= 124) Mean daily dose taken 73 mg	mmol/L	Lovastatin: Baseline 5.97 ± 0.61 2 yrs 4.03 ± 0.45 change -32.3% ± 7.0 Placebo: Baseline 6.01 ± 0.59 2 yrs 5.90 ± 0.68 change -1.8% ± 7.5	Lovastatin: Baseline 3.91 ± 0.62 2 yrs 2.41 ± 0.42 change -38.0% ± 12.3 Placebo: Baseline 4.00 ± 0.64 2 yrs 3.96 ± 0.63 change -0.9% ± 13.8	Lovastatin: Baseline 1.10 ± 0.26 2 yrs 1.18 ± 0.25 change +8.5 ± 10.3 Placebo: Baseline 1.11 ± 0.25 2 yrs 1.13 ± 0.24 change +2.3% ± 11.9	Lovastatin: Baseline 1.80 ± 0.83 2 yrs 1.36 ± 0.25 change -21.6% ± 20.2 Placebo: Baseline 1.80 ± 0.85 2 yrs 1.82 ± 1.07 change +3.5% ± 26.5	significant change from baseline for all lipid parameters with lovastatin (p<0.001)
Bradford et al, 1991	Lovastatin 20 mg once in evening (n = 1642) Lovastatin 40 mg once in evening (n = 1645) Lovastatin 40 mg daily (as 2 doses) (n = 1646) Lovastatin 80 mg daily (as 2 doses) (n = 1649) Placebo (n = 1663)	mg/dL	Lovastatin 20 mg once: Baseline 258 ± 21 48 wks no data change -17% ± 8 Lovastatin 40 mg once: Baseline 259 ± 20 48 wks no data change -22% ± 8 Lovastatin 40 mg twice: Baseline 259 ± 21 48 wks no data change -24% ± 8 Lovastatin 80 mg twice: Baseline 258 ± 21 48 wks no data change -29% ± 9 Placebo: Baseline 257 ± 20 48 wks no data change +0.7% ± 8	Lovastatin 20 mg once: Baseline 180 ± 21 48 wks no data change -24% ±11 Lovastatin 40 mg once: Baseline 180 ± 21 48 wks no data change -30% ±11 Lovastatin 40 mg twice: Baseline 181 ± 21 48 wks no data change -34% ±11 Lovastatin 80 mg twice: Baseline 180 ± 21 48 wks no data change -40% ±11 Placebo: Baseline 179 ± 20 48 wks no data change +1.0% ± 11	Lovastatin 20 mg oncepm: Baseline 45 ± 12.4 48 wks no data change +6.6% ± 13 Lovastatin 40 mgonce pm Baseline 45.2 ± 11.8 48 wks no data change +7.2% ± 13 Lovastatin 40 mg (as 2 doses): Baseline 45 ± 11.9 48 wks no data change +8.6% ± 13 Lovastatin 80 mg (as 2 doses): Baseline 45.2 ± 12.6 48 wks no data change +9.5% ± 13 Placebo: Baseline 44.8 ± 12 48 wks no data change +2.0% ± 12	Lovastatin 20 mg once: Baseline 152 no SD 48 wks no data change -10% no SD Lovastatin 40 mg once: Baseline 156 no SD 48 wks no data change -14% no SD Lovastatin 40 mg twice: Baseline 157 no SD 48 wks no data change -16% no SD Lovastatin 80 mg twice: Baseline 154 no SD 48 wks no data change -19% no SD Placebo: Baseline 156 no SD 48 wks no data change +4.0$ no SD	

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Brown et al 2001 (Abstract)	Rosuvastatin 5 mg (n=123) Rosuvastatin 10 mg (n=116) Pravastatin 20 mg (n=118) Simvastatin 20 mg (n=120)	mmol/L	Pravastatin 20 mg: Baseline 7.09 12 wks no data % change (SE) -18.5 (1.0) Simvastatin 20 mg: Baseline 7.09 12 wks no data % change (SE) -23.8 (1.0) Rosuvastatin 5 mg: Baseline 7.15 12 wks no data % change (SE) -28.0 (1.0) Rosuvastatin 10 mg: Baseline 7.05 12 wks no data % change (SE) -33.4 (1.0)	Pravastatin 20 mg: Baseline 4.87; 12 wks no data % change (SE) 12 wks -26.5 (1.3); 52 wks -31.5% (1.5) Simvastatin 20 mg: Baseline 4.86 12 wks no data % change (SE) 12 wks -34.6 (1.3); 52 wks -37.9% (1.4) Rosuvastatin 5 mg: Baseline 4.84 12 wks no data % change (SE) -39.1 (1.3); 52 wks -41.6% (1.4) Rosuvastatin 10 mg: Baseline 4.84 12 wks no data % change (SE) 12 wks -47.4 (1.3); 52 wks -48% (1.4)	Pravastatin 20 mg: Baseline 1.3 12 wks no data % change (SE) 12 wks 8.3 (1.2); 52 wks 4.5% (1.4) Simvastatin 20 mg: Baseline 1.32 12 wks no data % change (SE) 12 wks 8.8 (1.2); 52 wks 6.2% (1.3) Rosuvastatin 5 mg: Baseline 1.31 12 wks no data % change (SE)12 wks 8.2 (1.2); 52 wks 4.5% (1.3) Rosuvastatin 10 mg: Baseline 1.29 12 wks no data % change (SE)12 wks 11.9 (1.2); 52 wks 7.6% (1.3)	Pravastatin 20 mg: Baseline 2.01 12 wks no data % change (SE) 12 wks -11.4 (2.5); 52 wks -9.3% (2.7) Simvastatin 20 mg: Baseline 1.99 12 wks no data % change (SE) 12 wks -10.2 (2.5); 52 wks -14.1% (2.6) Rosuvastatin 5 mg: Baseline 2.18 12 wks no data % change (SE) 12 wks -17.6 (2.5); 52 wks -15.8% (2.6) Rosuvastatin 10 mg: Baseline 2.03 12 wks no data % change (SE) 12 wks -21.5 (2.5); 52 wks -18.1% (2.7)	None reported
Byington et al, 1995	Pravastatin 20 mg/day (n= 75) Placebo (n= 76) Once daily evening. Dose doubled if LDL >2.84 mmol/L & decreased to 10 mg if LDL was <2.33 mmol/L Number on different doses: 10 mg 4% 20 mg 23.5% 40 mg 72.5%	mg/dL	Pravastatin: Baseline 236 ± SE 2.86 Mean1-3 yrs 186 ± SE 2.5 change -21% Placebo: Baseline 234 ± SE 2.33 Mean1-3 yrs 235 ± SE 2.47 change no data	Pravastatin: Baseline 168 ± SE 2.2 Mean1-3 yrs 120 ± SE 2.2 change -28% Placebo: Baseline 164 ± SE2.0 Mean1-3 yrs 167 ± SE 2.2 change no data	Pravastatin: Baseline 42 ± SE 1.1 Mean1-3 yrs 41 ± SE 0.4 change no data Placebo: Baseline 40.5 ± SE 1.0 Mean1-3 yrs 40.1 ± SE 1.0.4 change no data	Pravastatin: Baseline 160 ± SE 6.6 Mean1-3 yrs 155 ± SE 5.0 change -14% Placebo: Baseline 182 ± SE 11 Mean1-3 yrs 179 ± SE 5.0 change no data	Pravastatin signifiantly more effective than placebo at changing total cholesterol, LDL & triglycerides (p<0.001), but not HDL.

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Celis et al, 1994	Pravastatin (n= 25) Placebo (n= 25) Dose increased from 10 mg to 20 mg at end of mth 1 & to 40 mg at end of mth 2. Pts remained on 40 mg daily.	mg/dL	NB 4 mth data provided Pravastatin: Baseline 277 ± 6 4 mths 213 no SD (5.5 mmol/L) change -22% no SD Placebo: Baseline 285 ± 7 4 mths 282 no SD (7.3 mmol/L) absolute change -3.0	NB 4 mth data provided Pravastatin: Baseline 197 ± 6 4 mths 128 no SD (3.3 mmol/L) absolute change -69 Placebo: Baseline 200 ± 9 4 mths 193 no SD (5.0 mmol/L) absolute change -7.0	NB 4 mth data provided Pravastatin: Baseline 48 ± 3 4 mths 49.5 no SD (1.28 mmol/L) Absolute change +1.0 Placebo: Baseline 51 ± 4 4 mths 51.8 absolute change +0.8	NB 4 mth data provided Pravastatin: Baseline 166 ± 18 4 mths unchanged Placebo: Baseline 169 ± 22 4 mths unchanged	
Chan et al, 1996	Simvastatin 10 mg (n=38) Placebo (n=38) Once daily evening	mg/dL	Simvastatin: Baseline 281 ± 18; 12 mths 205 ± 15; change no data Placebo: Baseline 286 ± 26; 12 wks 281 ± 22; change no data	Simvastatin: Baseline 209 ± 12; 12 wks 207 ± 19; change no data Placebo: Baseline 204 ± 22; 12 wks 207 ± 19; change no data	Simvastatin: Baseline 49 ± 7.0; 12 wks 52.3 ± 7.9; change no data Placebo: Baseline 48 ± 8; 12 wks 48.6 ± 7.7; change no data	Simvastatin: Baseline 115 ± 35; 12 wks 106 ± 25; change Placebo: Baseline 126 ± 34; 12 wks 123 ± 29; change	Significant change from baseline & from placebo with simvastatin 10 mg at 12 wks for total cholesterol, LDL and triglycerides but not HDL
Chan et al, 1996	Pravastatin 15 mg (n= 48) Placebo (n= 48) Once in evening	mg/dL	Pravastatin: Baseline 7.3 ± 0.5 12 mths 5.5 no SD change -25% no SD Placebo: Baseline 7.2 ± 0.6 12 mths 6.9 no SD change -5.1% no SD	Pravastatin: Baseline 5.3 ± 0.5 12 mths 3.7 no SD change -30.2% no SD Placebo: Baseline 5.4 ± 0.4 12 mths no data change -7.6% no SD		Pravastatin: Baseline 1.7 ± 0.4 12 mths 1.5 no SD change -11% no SD Placebo: Baseline 1.6 ± 0.4 12 mths no data change -2.6% no SD	
Chan et al, 1996b	Pravastatin 10 mg (n= 25) Placebo (n=25) Once daily evening	mg/dL	Pravastatin: Baseline 284 ± 14; 20 wks 217 ± 15; change -23.5% Placebo: Baseline 283 ± 20; 20 wks 274 ± 13; change -3.0%	Pravastatin: Baseline 207 ± 20; 20 wks 148 ± 16; change -28.5% Placebo: Baseline 208 ± 22; 20 wks 200 ± 13; change -3.1%	Pravastatin: Baseline 46.4 ± 8.1 20 wks 49.5 ± 7.3 change 6.5% Placebo: Baseline 45.6 ± 8.8 20 wks 45.2 ± 8.2 change -0.5%	Pravastatin: Baseline 135 ± 46 20 wks 123 ± 28 change -9.1 Placebo: Baseline 144 ± 46 20 wks 139 ± 27 change -0.2	Significant change from baseline & from placebo with pravastatin 10 mg at 20 wks for total cholesterol & LDL ($p<0.05$). Significant changes from baseline only for triglycerides &HDL ($p<0.05$).

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Chan et al, 1995	Pravastatin 10 mg (n= 30) Placebo (n= 30)	mg/dL	Pravastatin: Baseline 279 ± 6 6 mths 222 no SD Change -20% no SD Placebo: Baseline 285 ± 7 6 mths 283 no SD Change no data	Pravastatin: Baseline 200 ± 9 6 mths 158 no SD Change -25% no SD Placebo: Baseline 210 ± 8 6 mths 218 no SD Change no data	Pravastatin: Baseline 47 ± 5 6 mths 49 no SD Change +5% no SD Placebo: Baseline 46 ± 4 6 mths 49 no SD Change no data	Pravastatin: Baseline 127 ± 18 6 mths 116 no SD Change -8% no SD Placebo: Baseline 129 ± 22 6 mths 127 no SD Change no data	Pravastatin significantly more effective than placebo at reducing total cholesterol & LDL. No significant difference for other parameters
Crepaldi et al, 1991	Pravastatin (n= 193) 40 mg/day evening	mmol/L	Pravastatin: Baseline 9.2 ± 1.4 24 wks 7.0 ±1.4 change -23% no SD Gemfibrozil: Baseline 9.1 ± 1.4 24 wks 7.8 ± 1.6 change -14% no SD	Pravastatin: Baseline 7.2 ± 1.4 24 wks 5.1 ± 1.5 change -30% no SD Gemfibrozil: Baseline 7.0 ± 1.5 24 wks 5.9 ± 1.7 change -16% no SD	Pravastatin: Baseline 1.2 ± 0.3 24 wks 1.3 ± 0.4 change +5% no SD Gemfibrozil: Baseline 1.3 ± 0.3 24 wks 1.4 ± 0.4 change +13% no SD	Pravastatin: Baseline 1.5 ± 0.5 24 wks 1.4 ± 0.5 change -5% no SD Gemfibrozil: Baseline 1.6 ± 0.6 24 wks 0.9 ± 0.4 change -13% no SD	Significant reductions from baseline with pravastatin & gemfibrozil for all lipid parameters ($p<0.01$)
D'Agostino et al, 1992	Lovastatin evening (n= 52) Initial 20 mg dose wasdoubled after 6 wks if LDL > 160 mg/dL in stratum I or >130 mg/dL in stratum II Gemfibrozil 1200 mg/day given as 600 mg twice (n= 52) Dose remained constant	mg/dL	Lovastatin: Baseline 284 18 wks no data absolute change -62 Gemfibrozil: Baseline 293 18 wks absolute change -37	Lovastatin: Baseline 209 18 wks no data absolute change -67 Gemfibrozil: Baseline 212 18 wks no data absolute change -29	Lovastatin: Baseline 44 18 wks no data absolute change +5 Gemfibrozil: Baseline 45 18 wks no data absolute change +8	Lovastatin: Baseline 164 18 wks no data absolute change -15 Gemfibrozil: Baseline 172 18 wks no data absolute change -74	Lovastatin significantly more effective than gemfibrozil at reducing total cholesterol & LDL ($p<0.001$) Gemfibrozil significantly more effective than lovastatin at changing triglycerides & HDl ($p<0.001$)

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Dart et al, 1997	Atorvastatin 10 mg (n=132) Dose doubled of LDL target not reached at wk 10 (64/132) Simvastatin 10 mg (n=45) Dose doubled of LDL target not reached at wk 10 (28/45) Completed 95%	mmol/L	Atorvastatin: Baseline 7.6 ± 0.1; 52 wks no data; change -30% ± SE 0.8 Simvastatin: Baseline 7.3 ± 0.2; 52 wks no data; change -25% ± SE 1.3	Atorvastatin: Baseline 5.5 ± 0.1; 52 wks no data; change -38% ± SE1.0 Simvastatin: Baseline 5.4 ± 0.1; 52 wks no data; change -33% ± SE 1.5	Atorvastatin: Baseline 1.09 ± SE 0.02 52 wks no data change +7 ± SE 1.4 Simvastatin: Baseline 1.03 ± SE 0.03 52 wks no data change +7 ± SE 2.2	Atorvastatin: Baseline 2.1 ± 0.1; 52 wks no data; change -21% ± SE 2.4 Simvastatin: Baseline 2.0 ± 0.1; 52 wks no data; change -12% ± SE 3.8	Significantly greater reduction in LDL, total cholesterol & triglycerides from baseline to 52 wks with atorvastatin than with simvastatin (p<0.005)
Davidson et al, 1991	Prvastatin 40 mg (n=26) Placebo (n= 27) Probucol 1000 mg (n= 29) Pravastatin + probucol (n= 29) Probucol 500 mg given twice daily All other treatments given once daily evening	mmol/L	Pravastatin: Baseline 7.52 ± SEM 0.2 16 wks 5.7 ± SEM 0.2 change -24% ± SEM 2.1 Probucol: Baseline 7.73 ± SEM 0.24 16 wks 6.7 ± SEM 0.25 change -12.6% ± SEM 2.3 Placebo: Baseline 7.28 ± SEM 0.14 16 wks 7.05 ± SEM 0.22 change -3.3% ± SEM 2.7 Combination: Baseline 7.5 ± SEM 0.24 16 wks 5.0 ± SEM 0.15 change -33.2% ± SEM 1.8	Pravastatin: Baseline 5.43 ± SEM 0.19 16 wks 3.7 ± SEM 0.17 change -32% ± SEM 2.4 Probucol: Baseline 5.67 ± SEM 0.24 16 wks 4.94 ± SEM 0.24 change -11.2% ± SEM 3.1 Placebo: Baseline 5.13 ± SEM 0.13 16 wks 4.97 ± SEM 0.18 change -3.46% — SEM 3.49 Combination: Baseline 5.27 ± SEM 0.21 16 wks 3.29 ± SEM 0.14 change -37.5% ± SEM 2.2	Pravastatin: Baseline 1.1 ± SEM 0.04 16 wks 1.16 ± SEM 0.05 change +8.9 ± SEM 4.2 Probucol: Baseline 1.14 ± SEM 0.05 16 wks 0.82 ± SEM 0.06 change -26.1% ± SEM 2.7 Placebo: Baseline 1.26 ± SEM 0.07 16 wks 1.20 ± SEM 0.06 change -1.5% ± SEM 3.8 Combination: Baseline 1.25 ± SEM 0.06 16 wks 0.92 ± SEM 0.05 change -24% ± SEM 2.9	Pravastatin: Baseline 1.88 ± SEM 0.17 16 wks 1.55 ± SEM 0.16 change -17.6% ± SEM 5.33 Probucol: Baseline 1.68 ± SEM 0.14 16 wks 1.62 ± SEM 0.15 change -6.36% ± SEM 5.92 Placebo: Baseline 1.65 ± SEM 0.15 16 wks 1.66 ± SEM 0.15 change -3.13% ± SEM 6.4 Combination: Baseline 1.83 ± SEM 0.17 16 wks 1.43 ± SEM 0.13 change -22.8% ± SEM 4.9	Significant change in total cholesterol, LDL, HDL & triglycerides with pravastatin or combiination therapy (p<0.05) Significant change in total cholesterol, LDL, & HDL with probucol (p<0.05) No significant change for any outcome with placebo. Pravastatin was significantly more effective than probucol (p<0.05)

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Davidson et al, 1997	Atorvastatin 10 mg (n= 707) Lovastatin 20 mg (n= 191) Placebo (n=133) - cannot use placebo data as no baseline lipids provided	mmol/L	Atorvastatin: Baseline 7.1 ± SE 0.03 16 wks no data change -27% ± 0.4 Lovastatin: Baseline 7.1 ± SE 0.05 16 wks no data change -19% ± 0.6	Atorvastatin: Baseline 5.0 ± SE 0.02 16 wks no data change -36% ± SE 0.5 Lovastatin: Baseline 4.9 ± SE 0.04 16 wks no data change -27% ± SE 0.8	Atorvastatin: Baseline 1.3 ± 0.01 16 wks no data change +7% ± 0.5 Lovastatin: Baseline 1.3 ± 0.02 16 wks no data change +7% ± 0.9	Atorvastatin: Baseline 2.0 ± 0.03 16 wks no data change -17% ± 1.1 Lovastatin: Baseline 2.1 ± 0.05 16 wks no data change -6% ± 1.9	Atorvastatin 10 mg significantly more effective than lovastatin 20 mg at reducing total cholesterol, triglycerides & LDL (p<0.05)
Davidson et al. 2001 Now published as [Davidson et al, 2002]	Rosuvastatin 5 mg (n=129) Rosuvastatin 10 mg (n=130) Placebo (n=132) Atorvastatin 10 mg (n=128)	mmol/L	Placebo: Baseline 7.06 SD ± 0.71 12 wks no data % change (SE) 0 (0.9) Rosuvastatin 5 mg: Baseline 7.18 ± 0.61 12 wks no data % change (SE) -28 (1.0) Rosuvastatin 10 mg: Baseline 7.03 ± 0.59 12 wks no data % change (SE) -30 (1.0) Atorvastatin 10 mg: Baseline 7.04 ± 0.64 12 wks no data % change (SE) -25 (1.0)	Placebo: Baseline 4.83 SD ± 0.54; 12 wks no data % change (SE) 0 (1.2) Rosuvastatin 5 mg: Baseline 4.87 ±0.50 12 wks no data % change (SE) -40 (1.3) Rosuvastatin 10 mg: Baseline 4.77 ±0.44 12 wks no data % change (SE) -43 (1.3) Atorvastatin 10 mg: Baseline 4.80 ± 0.51 12 wks no data % change (SE) -35 (1.3)	Placebo: Baseline 1.26 SD ± 0.29 12 wks no data % change (SE) +4 (1.0) Rosuvastatin 5 mg: Baseline 1.36 ±0.32 12 wks no data % change (SE) +13 (1.0) Rosuvastatin 10 mg: Base_ine 1.28 ± 0.29 12 wks no data % change (SE) +12 (1.0) Atorvastatin 10 mg: Baseline 1.30 ± 0.30 12 wks no data % change (SE) +8 (1.0)	Placebo: Baseline 2.11 ± 0.74 12 wks no data % change (SE) -1 (2.3) Rosuvastatin 5 mg: Baseline 2.10 ± 0.87 12 wks no data % change (SE) -17 (2.4) Rosuvastatin 10 mg: Baseline 2.13 ± 0.75 12 wks no data % change (SE) -19 (2.4) Atorvastatin 10 mg: Baseline 2.06 ± 0.81 12 wks no data % change (SE) -19 (2.4)	Significantly greater improvement in LDL with rosuvastatin 5 mg (p<0.01) or 10 mg (p<0.001) than with atorvastatin. Significantly greater improvemnt in total cholesterol with rosuvastatin 5 mg or 10 mg (p<0.05) than with atorvastatin. Significantly greater improvement in HDL with rosuvastatin 5 mg (p<0.01) or 10 mg (p<0.001) than with atorvastatin. No significant differences between groups for triglycerides.

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Dobs et al, 2000	Simvastatin 20 mg (n= 40) Simvastatin 40 mg: (n= 41) Pravastatin 40 mg (n= 39) Placebo (n= 39) Given once daily Number completed study: Sim 20 mg 37 Sim 40 mg 34 Prav 40 mg 37 Placebo 30	mg/dL	Simvastatin 20 mg: Baseline 262 no SD 24 wks no data Change -25.8% ± 8.5 Simvastatin 40 mg: Baseline 258 no SD 24 wks no data Change -26.8% ± 12.3 Pravastatin 40 mg: Baseline 251 no SD 24 wks no data Change -23.6% ± 10.3 Placebo: Baseline 262 no SD 24 wks no data Change -1.0% ± 10.4	Simvastatin 20 mg: Baseline 186 no SD 24 wks no data Change -33.1% ± 10.5 Simvastatin 40 mg: Baseline 183 no SD 24 wks no data Change -34.3% ± 15.4 Pravastatin 40 mg: Baseline 182 no SD 24 wks no data Change -30.1% ± 12.6 Placebo: Baseline 186 no SD 24 wks no data Change +0.6% ± 12.1	Simvastatin 20 mg: Baseline 44 no SD 24 wks no data Change +7.9% ± 12.2 Simvastatin 40 mg: Baseline 39 no SD 24 wks no data Change +5.0% ± 13.0 Pravastatin 40 mg: Baseline 42 no SD 24 wks no data Change +2.5% ± 12.3 Placebo: Baseline 41 no SD 24 wks no data Change -5.4% ± 11.1	Simvastatin 20 mg: Baseline 191 no SD 24 wks no data Change -24.6% ± 23/1 Simvastatin 40 mg: Baseline 211 no SD 24 wks no data Change -14.5% ± 27.4 Pravastatin 40 mg: Baseline 156 no SD 24 wks no data Change -15.7% ± 46.6 Placebo: Baseline 214 no SD 24 wks no data Change +5.7% ± 46.6	All active treatments were significantly better at reducing total cholesterol, LDL, triglycerides & HDL than placebo

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Farnier & the Cerivastatin Study Group, 1998	Cerivastatin 0.1 mg (n=166) 0.2 mg (n=171) 0.3 mg (175) Gemfibrozil 1200 mg (n=160) Placebo (n=79)	mg/dL		Cerivastatin 0.1 mg:mg/dL Baseline 201.0 ± 37.6 16 wk no data change -15.1% Cerivastatin 0.2 mg: Baseline 195.7 ± 33.6 16 wk no data change -23.0% Cerivastatin 0.3 mg: Baseline 200.6 ± 30.3 16 wkno data change -24.2 Gemfibrozil 1200 mg: Baseline 201.7 ± 37.6 16 wk no data change -7.5`% Placebo: Baseline 199.5 ± 34.3 16 wk no data change -0.6 %	No data	Cerivastatin 0.1 mg (mg/dL): Baseline 281.5 ± 67.2 16 wk no data change -14.8% Cerivastatin 0.2 mg: Baseline 272.0 ± 63.3 16 wk no data change -11.7% Cerivastatin 0.3 mg: Baseline 276.1 ± 80.0 16 wk no data change -20.3% Gemfibrozil: Baseline 275.9 ± 81.1 16 wk no data change -50.3% Placebo: Baseline ? 16 wk ? change +2.1%	Significant benefit over placebo for change from baseline in LDL cholesterol for all doses of cerivastatin ($p<0.001$) and gemfibrozil ($p<0.05$). Significant change in triglyceride compared with placebo with all doses of cerivastatin (0.1 or 0.3 mg $p<0.05$; 0.2 mg $p<0.01$) and gemfibrozil ($p<0.05$). No significant difference between groups or doses for adverse events.

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Farnier et al, 1992	Simvastatin 10-40 mg daily (n= 82) Dose doubled from 10 mg after 6 wks & to 40 mg after 12 wks if total cholesterol >5.2 mmol/L Doses taken at wk 18: 10 mg 11/82 20 mg 20/82 40 mg 51/82 Ciprofibrate 100 mg daily (n= 82) Dose maintained throughout	mmol/L	Simvastatin: Baseline 8.7 ± 1.8 18 wks no data change -30% ± 13 Ciprofibrate: Baseline 8.3 ± 1.7 18 wks no data change -16% ± 15	Simvastatin: Baseline 6.6 ± 1.8 18 wks no data change -41% ± 11 Ciprofibrate: Baseline 6.4 ± 1.8 18 wks no data change -20% ± 18	Simvastatin: Baseline 1.4 ± 0.4 18 wks no data change +8.2% ± 23 Ciprofibrate: Baseline 1.3 ± 0.4 18 wks no data change +9.7% ± 18	Simvastatin: Baseline 1.7 ± 1.1 18 wks no data change -11% ± no SD Ciprofibrate: Baseline 1.8 ± 0.8 18 wks no data change -34% ± no SD	Simvastatin significantly better at reducing total & LDL cholesterol than ciprofibrate ($p<0.01$). Ciprofibrate significantly better at reducing triglycerides than simvastatin ($p<0.01$). No significant difference between treatments for HDL.
Fogari et al, 1997	Pravastatin 20 mg (n=106) Once daily Acipimpox 750 (n=106) 250 mg given 3 x daily	mg/dL	Pravastatin: Baseline 265 ± 33 12 wks 204 ± 34 change no data Acipimpox: Baseline 265 ± 33 12 wks 225 ± 33 change no data	Pravastatin: Baseline 173 ± 30 12 wks 119 ± 28 change no data Acipimpox: Baseline 171 ± 29 12 wks 142 ± 28 change no data	Pravastatin: Baseline 38 ± 7.6 12 wks 40 ± 8.0 change no data Acipimpox: Baseline 38 ± 7.5 12 wks 44 ± 9.7 change no data	Pravastatin: Baseline 287 ± 102 12 wks 237 ± 89 change no data Acipimpox: Baseline 292 ± 101 12 wks 192 ± 66 change no data	Pravastatin: significant change from baseline for all lipids & triglycerides ($p<0.0001$). Significantly better than acipimpox for total & LDL cholesterol ($p<0.01$). Acipimpox: significant change from baseline for all lipids & triglycerides ($p<0.0001$). Significantly better than pravastatin for HDL ($p<0.01$).

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Frederiksen et la, 1993	Pravastatin 20 mg (n= 110) Pravastatin 40 mg (n=67) Both groups analysed together Placebo (n= 96)	mmol/L	Pravastatin 20/40 mg: Baseline 7.0 ± 0.6 26 wks 5.9 ± 0.8 change no data Placebo: Baseline 7.0 ± 0.6 26 wks 7.3 ± 0.8 change no data	Pravastatin 20/40 mg: Baseline 4.9 ± 0.6 26 wks 3.8 ± 0.8 change no data Placebo: Baseline 5.0 ± 0.6 26 wks 5.3 ± 0.8 change no data	Pravastatin: Baseline 1.32 ± 0.35 26 wks 1.40 ± 0.4 change 0.08 no SD Placebo: Baseline 1.34 ± 0.38 26 wks 1.38 ± 0.38 change 0.04 no SD	Pravastatin 20/40 mg: Baseline 1.8 ±0.9 26 wks 1.6 ±0.8 change no data Placebo: Baseline 1.7 ± 0.8 26 wks 1.5 ± 0.6 change no data	
Frohlich et al, 1993	Lovastatin Stratum I (n= 77) Lovastatin StratumII (n= 72) 20 / 40/ 80mg daily Simvastatin Stratum I (n= 74) Simvastatin Stratum II (n= 75) 10 / 20 / 40 mg daily Dose doubled if total cholesterol >5.2 at 6 and 12 wks	mmol/L	Lovastatin Stratum I: Baseline 7.1 ± 0.5 18 wks 5.2 ± 0.7 change no data Lovastatin Stratum II: Baseline 9.2 ± 1.3 18 wks 9.4 ± 1.4 change no data Simvastatin Stratum I: Baseline 7.1 ± 0.6 18 wks 5.2 ± 0.6 change no data Simvastatin Stratum II: Baseline 9.4 ± 1.4 18 wks 6.5 ± 1.1 change no data	Lovastatin Stratum I: Baseline 5.2 ± 0.6 18 wks 3.4 ± 0.6 change no data Lovastatin Stratum II: Baseline 7.3 ± 1.4 18 wks 4.6 ± 1.4 change no data Simvastatin Stratum I: Baseline 5.2 ± 0.5 18 wks 3.4 ± 0.6 change no data Simvastatin Stratum II: Baseline 7.5 ± 1.6 18 wks 4.7 ± 1.2 change no data	Lovastatin Stratum I: Baseline 1.1 ± 0.3 18 wks 1.1 ± 0.3 change no data Lovastatin Stratum II: Baseline 1.12 ± 0.3 18 wks 1.2 ± 0.3 change no data Simvastatin Stratum I: Baseline 1.2 ± 0.3 18 wks 1.2 ± 0.3 change no data Simvastatin Stratum II: Baseline 1.1 ± 0.3 18 wks 1.2 ± 0.3 change no data	Lovastatin Stratum I: Baseline 2.0 ± 0.9 18 wks 1.7 ± 0.8 change no data Lovastatin Stratum II: Baseline 1.9 ± 0.8 18 wks 1.5 ± 0.7 change no data Simvastatin Stratum I: Baseline 2.1 ± 0.9 18 wks 1.7 ± 0.8 change no data Simvastatin Stratum II: Baseline 1.9 ± 0.9 18 wks 1.5 ± 0.7 change no data	

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Giannini et al, 1994	Pravastatin (n=not stated, assume 24) Dose increased from 10 mg to 20 mg to 60 mg/day Lovastatin (n=not stated, assume 24) Dose increased from 20 mg to 40 mg to 80 mg/day	md/dL	Pravastatin: Baseline 298 ± 31 18 wks 227 ± 33 change no data Lovastatin: Baseline 302 ± 42 18 wks 207 ± 39 change no data	Pravastatin: Baseline 215 ± 33 18 wks 148 ± 32 change no data Lovastatin: Baseline 226 ± 51 18 wks 124 ± 37 change no data	Pravastatin: Baseline 46 ± 13 18 wks 53 ± 16 change no data Lovastatin: Baseline 50 ± 11 18 wks 56 ± 12 change no data	Pravastatin: Baseline 172 ± 56 18 wks 138 ± 46 change no data Lovastatin: Baseline 160 ± 68 18 wks 120 ± 50 change no data	
Greten et al, 1994	Fluvastatin 40 mg daily (n= 64) Bezfibrate 400 mg daily (n= 67)	mg/dL	Fluvastatin: Baseline 353 ± 89 12 wks no data change -17.% ± 10 Bezfibrate: Baseline 340 ± 77 12 wks no data change -13% ± 12	Fluvastatin: Baseline 269 ± 89 12 wks no data change -23% ± 12 Bezfibrate: Baseline 257 ± 76 12 wks no data change -17% ± 15	Fluvastatin: Baseline 55 ± 12 12 wks no data change +2.3% ± 14 Bezfibrate: Baseline 55 ± 13 12 wks no data change +12% ± 15	Fluvastatin: Baseline 143 ± 48 12 wks no data change -2.2% ± 35 Bezfibrate: Baseline 138 ± 59 12 wks no data change -28% ± 26	Significant change from baseline in total cholesterol & LDL with fluvastatin & bezfibrate, also for HDL & triglycerides with bezfibrate only ($p<0.01$).
Guillen et al, 1995	Pravastatin 10 mg (n= 76 analysed) Placebo (n= 74 analysed) Dose doubled if LDL targets not reached after 10-12 wks	mg/dL	Pravastatin: Baseline 233 ± 15 26 wks 205 ± 31 change -12% Placebo: Baseline 234 ± 14 26 wks 233 ± 34 change -0.4%	Pravastatin: Baseline 157 ± 17 26 wks 125 ± 29 change -20% Placebo: Baseline 156 ± 18 26 wks 158 ± 36 change +1.2&	Pravastatin: Baseline 42 ± 12 26 wks 45 ± 10 change +7.6% Placebo: Baseline 43 ± 10 26 wks 45 ± 12 change +3.7%	Pravastatin: Baseline 171 ± 59 26 wks 164 ± 74 change -3.7% Placebo: Baseline 162 ± 59 26 wks 158 ± 74 change -2.4%	

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Haffner et al, 1995	Simvastatin 10 mg in evening (n= 88) Simvastatin 20 mg in morning (n= 83) Simvastatin 20 mg in evening (n= 86) Placebo (n= 86)	mg/dL	Simvastatin 10 mg pm: Baseline 278 ± SE 3.0 24 wks no data change -55.2 ± 3.36 (-19.9%) Simvastatin 20 mg am: Baseline 281 ± SE 3.1 24 wks no data change -58.5 ± 3.5 (-20.9%) Simvastatin 20 mg pm: Baseline 279 ± SE 3.1 24 wks no data change -68.8 ± 3.4 (-24.7%) Placebo: Baseline 279 ± SE 3.0 24 wks no data change +4.4 ± 3.4 (+1.5%)	Simvastatin 10 mg pm: Baseline 195 ± SE 2.7 24 wks no data change -57.4 ± SE 3.0 (-27.6%) Simvastatin 20 mg am: Baseline 194 ± SE 2.8 24 wks no data change -56.5 ± SE 3.1 (-28.1%) Simvastatin 20 mg pm: Baseline 193 ± SE 2.8 24 wks no data change -60 ± SE 3.0 (-34.3%) Placebo: Baseline 194 ± SE 2.7 24 wks no data change 3.1 ± SE 3.0 (+1.6%)	Simvastatin 10 mg pm: Baseline 50.9 ± SE 1.5 24 wks no data change 2.2 ± SE 0.7 (+4.3%) Simvastatin 20 mg am: Baseline 50.9 ± SE 1.5 24 wks no data change 2.7 ± SE 0.8 (+5.3%) Simvastatin 20 mg pm: Baseline 52 ± SE 1.5 24 wks no data change 1.3 ± SE 0.8 (+2.5%) Placebo: Baseline 52.2 ± SE 1.5 24 wks no data change 1.5 ± SE 0.7 (+2.8%)	Simvastatin 10 mg pm: Baseline 141 (95% CI 130 to 155) 24 wks no data change -19.2 ± 6.5 (-13.6%) Simvastatin 20 mg am: Baseline 162 (95% CI 146 to 179) 24 wks no data change -25.7 ± 6.7 (-15.9%) Simvastatin 20 mg pm: Baseline 161 (95% CI 146 to 179) 24 wks no data change -21.3 ± 6.6 (-13.2%) Placebo: Baseline 148 (95% CI 134 to 164) 24 wks no data change -0.4 ± SE 6.5 (-0.3%)	Change from baseline to 24 wks was significantly difference for all doses of simvastatin but not placebo
Hagen et al, 1994	Fluvastatin 20/40 mg (n= 100) 20 mg dose doubled after 6 wks on treatment Cholestyramine 4/8 g (n=48) 4 g dose doubled after 1 wk on treatment	mg/dL	Fluvastatin: Baseline 325 ± 58 12 wks no data change -22% ± 8.8 Cholestyramine: Baseline 325 ± 46 12 wks no data change -25% ± 11	Fluvastatin: Baseline 249 ± 59 12 wks no data change -28% ± 11 Cholestyramine: Baseline 247 ± 46 12 wks no data change -35% ± 14	Fluvastatin: Baseline 49 ± 13 12 wks no data change +3.7% ± 11 Cholestyramine: Baseline 50 ± 12 12 wks no data change +3.7% ± 12	Fluvastatin: Baseline 132 ± 54 12 wks no data change -11% ± 29 Cholestyramine: Baseline 137 ± 55 12 wks no data change +12% ± 3.0	Both treatments: significant change from baseline for all lipid levels ($p<0.001$ except HDl which was $p<0.01$). Cholestyramine significantly more effective at reducing total & LDL cholesterol than fluvastatin ($p<0.001$).

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Hunninghake et al, 1990 Efficacy and safety of pravastatin	Pravastatin 10 mg (n=65) Pravastatin 20 mg (n=56) Pravastatin 40 mg (n=59) Placebo (n=88)	mmol/L	Pravastatin 10 mg: Baseline 7.86 mmol/L; 12 wk 6.88 mmol/L; % change -12.9 mmol/L Pravastatin 20 mg Baseline 8.22 mmol/L; 12 wk 6.80 mmol/L; % change -17.4 mmol/L Pravastatin 40 mg: Baseline 7.86 mmol/L; 12 wk 6.06 mmol/L; % change -23.3 mmol/L Placebo: Baseline 7.94 mmol/L; 12 wk 8.24 mmol/L; % change +3.7 mmol/L	Pravastatin 10 mg: Baseline 229.1 (5.90 mmol/L); 12 wk 4.90 mmol/L; % change -17.5 mmol/L Pravastatin 20 mg Baseline 245.4 (6.36 mmol/L); 12 wk 4.94 mmol/L; % change -22.9 mmol/L Pravastatin 40 mg: Baseline 229.0 (5.90 mmol/L); 12 wk 4.11 mmol/L; % change -30.8 mmol/L Placebo: Baseline 232.6 (5.98 mmol/L); 12 wk 5.98 mmol/L; % change +3.3 mmol/L	Pravastatin 10 mg: Baseline 1.22 mmol/L; 12 wk 1.29 mmol/L; % change +5.6 mmol/L Pravastatin 20 mg Baseline 1.10 mmol/L; 12 wk 1.17 mmol/L; % change +5.6 mmol/L Pravastatin 40 mg: Baseline 1.22 mmol/L; 12 wk 1.30 mmol/L; % change +6.7 mmol/L Placebo: Baseline 1.18 mmol/L; 12 wk 1.19 mmol/L; % change +1.2 mmol/L	Pravastatin 10 mg: Baseline 1.41 mmol/L; 12 wk 1.26 mmol/L; % change -11.0 mmol/L Pravastatin 20 mg Baseline 1.42 mmol/L; 12 wk 1.21 mmol/L; % change -14.7 mmol/L Pravastatin 40 mg: Baseline 1.37 mmol/L; 12 wk 1.16 mmol/L; % change -15.4 mmol/L Placebo: Baseline 1.50 mmol/L; 12 wk 1.55 mmol/L; % change +3.5 mmol/L	Significant difference from baseline in LDL for all groups at all time-points (p<0.001). Reductions in LDL & total cholesterol were significantly greater with pravastatin 20 mg than with 10 mg (p<0.01) and greater with 40 mg than with 20 mg or 10 mg (p<0.001)
Isaacsohn et al, 2001	Cerivastatin 0.4 mg (n= 195) Cerivastatin 0.8 mg (n= 776) Pravastatin 40 mg: (n= 199) All pravastatin patients received placebo for 8 wks & then took pravastatin for 46 wks	mg/dL	Cerivastatin 0.4 mg: Baseline 276.6 52 wks no data Change -23.8% ± SE 0.74 Cerivastatin 0.8 mg: Baseline 275.2 52 wks no data Change -29% ± SE 0.42 Pravastatin: Baseline 266 46 wks no data Change -22.1% ± SE 0.73	Cerivastatin 0.4 mg: Baseline 191.3 52 wks no data Change -33.6 ± SE 0.98 Cerivastatin 0.8 mg: Baseline 190.1 52 wks no data Change -40.8 ± SE 0.55 Pravastatin: Baseline 183.3 46 wks no data Change -31.5% ± SE 0.96	Cerivastatin 0.4 mg: Baseline 48.3 52 wks no data Change +8.0% ± SE 0.98 Cerivastatin 0.8 mg: Baseline 48.8 52 wks no data Change +9.7% ± 0.55 Pravastatin: Baseline 48.3 46 wks no data Change +7.1% ± SE 0.96	Cerivastatin 0.4 mg: Baseline 185.3 52 wks no data Change -13.8 ± 2.07 Cerivastatin 0.8 mg: Baseline 183.3 52 wks no data Change -18.3 ± SE 1.17 Pravastatin: Baseline 172 46 wks no data Change -8.9% ± SE 2.02	Cerivastatin 0.8 mg was significantly more effective than 0.4 mg or pravastatin at reducing total cholesterol, LDL (p<0.0001) and triglycrides (p<0.05).Also significantly better at increasing HDL than pravastatin (p<0.05).

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Jacobson et al, 1995	Pravastatin 20 mg evening (n=182) Placebo (n= 63)	mg/dL	Pravastatin: Baseline 7.3 ± 0.1 12 wks 5.8 ± 0.1 change -20% Placebo: Baseline 7.3 ± 0.1 12 wks 7.0 ± 0.1 change -3.6%	Pravastatin: Baseline 5.4 ± 0.1 12 wks 4.0 ± 0.1 change -26% Placebo: Baseline 5.5 ± 0.1 12 wks 5.2 ± 0.1 change -5.0%	Pravastatin: Baseline 1.15 ± 0.02 12 wks 1.16 ± 0.04 change -0.4% Placebo: Baseline 1.2 ± 0.04 12 wks 1.2 ± 0.04 change +2.5%	Pravastatin: Baseline 1.5 ± 0.05 12 wks 1.4 ± 0.06 change -6% Placebo: Baseline 1.48 ± 0.1 12 wks 1.5 ± 0.1 change +6%	Pravastatin significantly better than placebo for total & LDL cholesterol & triglycerides, but not for HDL.
Jacotot et al, 1995b	Fluvastatin evening (n= 68) 40 mg for 4 wks then 80 mg/day (high dose given 2x daily) Pravastatin evening (n= 66) 20 mg for 4 wks then 40 mg/day (once daily)	mg/dL	Fluvastatin: Baseline 297 ± 54 16 wks232 ± 48 change -21% ± 13 Pravastatin: Baseline 308 ± 59 16 wks 252 ± 54 change -18% ± 10	Fluvastatin: Baseline 215 ± 53 16 wks 150 ± 48 change -30% ± 17 Pravastatin: Baseline 227 ± 61 16 wks 167 ± 55 change -26% ± 13	Fluvastatin: Baseline 52 ± 12 16 wks 56 ± 15 change +8% ± 17 Pravastatin: Baseline 55 ± 18 16 wks 59 ± 18 change +9% ± 17	Fluvastatin: Baseline 151 ± 67 16 wks 128 ± 81 change -15% ± 27 Pravastatin: Baseline 134 ± 55 16 wks 132 ± 83 change -3% ± 32	Significant change from baseline for all lipid parameters with pravastatin & for all except HDL with fluvastatin (p<0.01). Between group differences were not significant.
Joukhadar et al, 2001	Atorvastatin 10 mg (n= 33) Simvastatin 40 mg (n= 33) Pravastatin 40 mg (n= 33)	mg/dL	Atorvastatin: Baseline 6.5 ± 0.8 12 wks 5.0 ± 0.7 change -24% Simvastatin: Baseline 6.8 ± 0.8 12 wks 4.8 ± 1.0 change -29% Pravastatin: Baseline 6.7 ± 0.7 12 wks 5.2 ± 0.7 change -22%	Atorvastatin: Baseline 4.3 ±0.7 12 wks 2.7 ± 0.6 change -37% Simvastatin: Baseline 4.5 ± 0.9 12 wks 2.5 ± 0.9 change -45% Pravastatin: Baseline 4.3 ± 0.8 12 wks 3.0 ± 0.6 change -31%	Atorvastatin: Baseline 1.6 ± 0.4 12 wks 1.8 ± 0.4 change +8% Simvastatin: Baseline 1.8 ± 0.6 12 wks 1.8 ± 0.6 change +5% Pravastatin: Baseline 1.8 ± 0.5 12 wks 1.8 ± 0.5 change +1%	Atorvastatin: Baseline 1.3 ± 0.4 12 wks 1.0 ± 0.4 change -19% Simvastatin: Baseline 1.3 ± 0.7 12 wks 1.1 ± 0.6 change -13% Pravastatin: Baseline 1.3 ± 0.8 12 wks 1.1 ± 0.6 change -16%	Significant reductions in total cholesterol, LDL & triglycerides with all treatments (p<0.001). No significant differences between groups at p<0.05.

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Jukema et al, 1995	Pravastatin 40 mg (n=450) Placebo (n=434) Once daily (evening)	mmol/L	Pravastatin: Baseline 6.02 ± 0.9 2 yrs 4.9 ± 1.0 change -1.12 Placebo: Baseline 6.05 ± 0.9 2 yrs 6.1 ± 1.0 change +0.05	Pravastatin: Baseline 4.3 ± 0.78 2 yrs 3.2 ± 0.9 change -1.1 Placebo: Baseline 4.3 ± 0.78 2 yrs 4.4 ±0.87 change +0.1	Pravastatin: Baseline 0.93 ± 0.23 2 yrs 1.01 ± 0.27 change +0.08 Placebo: Baseline 0.93 ± 0.23 2 yrs 0.93 ± 0.24 change none	Pravastatin: Baseline 1.8 ± 0.8 2 yrs 1.5 ± 0.9 change -0.3 Placebo: Baseline 1.8 ± 0.8 2 yrs 1.7 ± 1.0 change -0.1	Significant change from baseline with pravastatin for total cholesterol, LDL, HDL and triglycerides at 24 mths
Keech et al, 1994	Simvastatin 20 mg (n= 208) Simvastatin 40 mg (n= 206) Placebo (n= 207) Once daily	mmol/L	Simvastatin 20 mg: Baseline 7.0 ± 1.3 3 yrs 5.3 ± 1.2 change -25.5% no SD Simvastatin 40 mg: Baseline 7.0 ± 1.22 3 yrs 5.1 ± 1.4 change -27.7% no SD Placebo: Baseline 7.0 ± 1.2 3 yrs 6.8 ± 1.3 change -2.6% no SD	Simvastatin 20 mg: Baseline 4.85 ± 1.13 3 yrs 2.9 ± 1.25 change -40.2% no SD Simvastatin 40 mg: Baseline 4.84 ± 1.04 3 yrs 3.15 ± 1.04 change -34.9% no SD Placebo: Baseline 4.71 ± 1.1 3 yrs 4.5 ± 1.33 change -4.5% no SD	Simvastatin 20 mg: Baseline 1.17 ± 0.35 3 yrs 1.21 ± 0.39 change +3.4% no SD Simvastatin 40 mg: Baseline 1.16 ± 0.34 3 yrs 1.31 ± 0.37 change +13% no SD Placebo: Baseline 1.16 ± 0.31 3 yrs1.17 ± 0.41 change +0.9% no SD	Simvastatin 20 mg: Baseline 2.63 ± 1.84 3 yrs 2.15 ± 1.24 change 18.3% no SD Simvastatin 40 mg: Baseline 2.47 ± 1.22 3 yrs 2.0 ± 1.0 change -19% no SD Placebo: Baseline 2.63 ± 1.49 3 yrs 2.56 ± 1.31 change -2.7% no SD	Simvastatin 40 mg & 20 mg were significantly more effective than placebo at changing total cholesterol, LDL ($p<0.0001$), HDL ($p<0.001$) and triglycerides ($p<0.05$) over 3 yrs.
LaRosa et al, 1994 Data for men	Lovastatin 20 mg (n= 144; M=27, F=107) Lovastatin 40 mg (n= 145; M=34, F=111) Placebo (n= 142; M=54, F=88) Once daily in evening	mmol/L	Lova 20 mg: Men Baseline 6.5 no SD 48 wks5.39 no SD Change -0.959 no SD Lova 40 mg: Men Baseline 6.65 no SD 48 wks5.02 no SD Change -1.533 no SD Placebo: Men Baseline 6.67 no SD 48 wks 5.39 no SD Change +0.248 no SD	Lova 20 mg: Men Baseline 4.62 no SD 48 wks 3.49 no SD Change -1.143 no SD Lova 40 mg: Men Baseline 4.74 no SD 48 wks3.18 no SD Change -1.425 no SD Placebo: Men Baseline 4.72 no SD 48 wks 4.75 no SD Change -0.197 no SD	Lova 20 mg: Men Baseline 1.14 no SD 48 wks 1.22 Change 0.08 no SD Lova 40 mg: Men Baseline 1.12 no SD 48 wks 1.19 Change 0.07 no SD Placebo: Men Baseline 1.16 no SD 48 wks1.22 no SD Change + 0.047	Lova 20 mg: Men Baseline 1.59 no SD 48 wks 1.50 no SD Change -0.180 no SD Lova 40 mg: Men Baseline 1.73 no SD 48 wks 1.50 no SD Change -0.380 no SD Placebo: Men Baseline 1.74 no SD 48 wks 1.76 no SD Change 0.017 no SD	

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
LaRosa et al, 1994 Data for women	Lovastatin 20 mg (n= 144; M=27, F=107) Lovastatin 40 mg (n= 145; M=34, F=111) Placebo (n= 142; M=54, F=88) Once daily in evening	mmol/L	Lova 20 mg: Women Baseline 6.90 no SD 48 wks 5.65 no SD Change -1.135 no SD Lova 40 mg: Women Baseline 6.84 no SD 48 wks 5.62 no SD Change -1.202 no SD Placebo: Women Baseline 7.00 no SD 48 wks7.08 no SD Change +0.08	Lova 20 mg: Women Baseline 4.74 no SD 48 wks 3.51 no SD Change -1.117 no SD Lova 40 mg: Women Baseline 4.66 no SD 48 wks 3.52 no SD Change -1.166 no SD Placebo: Women Baseline 4.72 no SD 48 wks4.88 no SD Change +0.153 no SD	Lova 20 mg: Women Baseline 1.14 no SD 48 wks 1.19 no SD Change +0.083 no SD Lova 40 mg: Women Baseline 1.12 no SD 48 wks1.15 no SD Change +0.072 no SD Placebo: Women Baseline 1.39 no SD 48 wks 1.33 no SD Change +0.021 no SD	Lova 20 mg: Women Baseline 1.66 no SD 48 wks 1.47 no SD Change -0.114 Lova 40 mg: Women Baseline 1.83 no SD 48 wks 1.53 no SD Change -0.265 no SD Placebo: Women Baseline 1.87 no SD 48 wks 1.91 no SD Change -0.142 no SD	
Lecerf, 1993	Simvastatin 10-40 mg daily daily (evening). (n=67) Gemfibrozil 900 mg once daily (evening) (n=69)	g/L	Simvastatin: Baseline: 3.24 ± 0.69; 18 wks no data; % change -26.5% Gemfibrozil: Baseline: 3.21± 0.72; 18 wks no data; % change -12.2%	Simvastatin: Baseline: 2.41 ± 0.68; 18 wks no data; % change -35.1% Gemfibrozil: Baseline: 2.33 ± 0.68; 18 wks no data; % change -13.0%	Simvastatin: Baseline: 0.5 ± 0.17; 18 wks no data; % change 12.3% Gemfibrozil: Baseline: 0.52 ± 0.17; 18 wks no data; % change 12.6%	Median values Simvastatin: Baseline: 1.66 ± 0.98; 18 wks no data; % change -21.9% Gemfibrozil: Baseline: 1.68 ± 0.88; 18 wks no data; % change -42.9%	Significantly greater reduction in LDL cholesterol after 18 wks with simvastatin than with gemfibrozil (p<0.01). Significant reduction in triglycerides, total & LDL cholesterol (p<0.01) at 6, 12 & 18 wks with simvastatin
Leichleitner et al, 1995	Simvastatin 10/20 mg daily (n= 32) Bezafibrate 600 mg/day (n= 31)	mg/dL	Simvastatin: Baseline 330.4 12 wks no data Change -23.9% ± 15.9 Bezafibrate: Baseline 331.2 12 wks no data Change -13.5% ± 12.4	Simvastatin: Baseline 249.7 12 wks no data Change -35/9% ± 17.4 Bezafibrate: Baseline 244.6 12 wks no data Change -17.2% ± 17.0	Simvastatin: Baseline 48.9 12 wks no data Change +19.5% ± 54.3 Bezafibrate: Baseline 48.7 12 wks no data Change +17.8% ± 31.5	Simvastatin: Baseline 198.4 12 wks no data Change -7.9% ± 45 Bezafibrate: Baseline 189.3 12 wks no data Change -21.3% ± 31.5	Simvastatin significantly more effective than bezafibrate at reducing total choelsterol & LDL (p<0.01).

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Leiter et al, 1999	Cerivastatin 0.05-0.3 mg/day (n= 260) Simvastatin 5-40 mg/day (n= 127) Once daily Lowest dose for 8 wks, then titrated up at 0.1 mg/day or 10 mg/day if LDL >3.36 mmol/L. Further titration at wks 16 & 24 if needed. Mean dose at end-point: Ceriv0.24 mg/day Simv 21.7 mg/day	mmol/L	Cerivastatin: Baseline 8.1 ± 1.7 32 wks no data change -16 no SD Simvastatin: Baseline 7.9 ± 1.5 32 wks no data change -23% no SD	Cerivastatin: Baseline 6.0 ± 1.7 32 wks no data change -23% no SD Simvastatin: Baseline 5.7 ± 1.5 32 wks no data change -32% no SD	Cerivastatin: Baseline 1.2 ± 0.3 32 wks no data change +9% no SD Simvastatin: Baseline 1.3 ± 0.3 32 wks no data change +11% no SD	Cerivastatin: Baseline 2.0 ± 0.7 32 wks no data change -9% no Sd Simvastatin: Baseline 1.2 ± 0.8 32 wks no data change -10% no SD	Significantly greater reduction in LDL & total cholesterol with simvastatin than with cerivastatin (p<0.05)
Lijnen et al, 1996	Pravastatin (n=) Placebo (n=) Once daily, evening Dose titrated from 10 mg to 20 mg to 40 mg at 4 wk intervals. Only 1 pt did not titrate up from 20 mg	mmol/L	Pravastatin: Baseline 7.2 no SD 6 mths 5.4 no SD change no data Placebo: Baseline 7.4 no SD 6 mths 7.5 no SD change no data	Pravastatin: Baseline 3.4 no SD 6 mths 2.3 no SD change no data Placebo: Baseline 3.3 no SD 6 mths 3.5 no SD change no data	Pravastatin: Baseline 1.25 no SD 6 mths 1.3 no SD change no data Placebo: Baseline 1.3 no SD 6 mths 1.3 no SD change no data	Pravastatin: **mg/dL** Baseline 168 no SD 6 mths 160 no SD change no data Placebo: Baseline 170 no SD 6 mths 168 no SD change no data	Pravastatin significantly better than placebo at reducing total cholesterol & LDL (p<0.001). No significant difference between treatments for HDLor triglycerides.

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Lintott et al, 1993	Simvastatin(n= 24) Pravastatin (n= 24) Dose titration up from 10 mg to 40 mg daily Dose /day by wk 18: Sim 10 mg 3/24 Sim 20 mg 3/24 Sim 40 mg 18/24 Prav 10 mg 1/24 Prav 20 mg 0/24 Prav 40 mg 22/24	mmol/L	Simvastatin: Baseline 8.6 ± 0.3 18 wks 5.8 ± 0.2 change (absolute) -2.8 Pravastatin: Baseline 8.4 ± 0.3 18 wks 6.7 ± 0.2 change (absolute) -1.7	Simvastatin: Baseline 6.5 ± 0.3 18 wks 4.1 ± 0.2 change (absolute) -2.5 Pravastatin: Baseline 6.3 ± 0.3 18 wks 4.6 ± 0.2 change (absolute) -1.7	Simvastatin: Baseline 1.1 ± 0.1 18 wks 1.2 ±0.1 change (absolute) +0.1 Pravastatin: Baseline 1.1 ± 0.1 18 wks 1.2 ±0.1 change (absolute) +0.1	Simvastatin: Baseline 1.7 ±0.2 18 wks 1.5 ± 0.2 change (absolute) -0.2 Pravastatin: Baseline 1.8 ±0.2 18 wks 1.8 ±0.2 change (absolute)	Significant change from baseline to 18 wks for both statins for total cholesterol, LDL & HDL but not triglycerides (p<0.01)
Lovastatin Pravastatin Study Group 1990	Lovastatin (n= 339) 20 mg/day for 6 wks, then 40 mg for 6 wks & 80 for last 6 wks Pravastatin (n=333) 10 mg/day for 6 wks, then 20 mg for 6 wks & 40 for last 6 wks	mg/dL	Lovastatin: Baseline 287 ± 45 18 wks no data change -18% ± 13 Pravastatin: Baseline 288 ± 47 18 wks no data change -19% ± 12	Lovastatin: Baseline 194 ± 48 18 wks no data change -39% ± 18 Pravastatin: Baseline 196 ± 49 18 wks no data change -27% ± 16	Lovastatin: Baseline 51 ± 16 18 wks no data change +19% ± 41 Pravastatin: Baseline 49 ± 16 18 wks no data change +16% ± 37	Lovastatin: Baseline 145 ± 80 18 wks no data change -22% ± 35 Pravastatin: Baseline 140 ± 206 18 wks no data change -15% ± 34	
Lye et al, 1998	Fluvastatin 40 mg once daily (n= 33) Placebo (n= 36)	mmol/L	Fluvastatin: Baseline 7.4 ± 0.9 12 wks no data change (absolute) -1.6 ± 0.7 Placebo: Baseline 7.5 ± 0.8 12 wks no data change (absolute) -0.2 ± 0.6	Fluvastatin: Baseline 5.2 ± 0.7 12 wks no data change (absolute) -1.4 ± 0.5 Placebo: Baseline 5.3 ± 0.6 12 wks no data change (absolute) -0.1 ± 0.5	Fluvastatin: Baseline 1.4 ± 0.3 12 wks no data change (absolute) +0.1 ± 0.2 Placebo: Baseline 1.3 ± 0.3 12 wks no data change (absolute) -0.0 ± 0.1	Fluvastatin: Baseline 1.6 ± 0.6 12 wks no data change (absolute) -0.3 ± 0.3 Placebo: Baseline 2.0 ± 0.8 12 wks no data change (absolute) -0.1 ± 0.5	Significant change from baseline to 12 wks with fluvastatin for all lipid parameters (p<0.05). Significantly more effective than placebo (p=0.05).

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
MAAS investigators, 1994	Simvastatin 20 mg (n= 193) Placebo (n= 188) Once daily evening	mmol/L	Simvastatin: Baseline 6.4 ± 0.7 4 yrs 5.0 ± 0.8 change no data Placebo: Baseline 6.4 ± 0.8 4 yrs 6.4 ± 0.7 change no data	Simvastatin: Baseline 4.4 ± 0.7 4 yrs 3.0 ± 0.7 change no data Placebo: Baseline 4.5 ± 0.8 4 yrs 4.4 ± 0.7 change no data	Simvastatin: Baseline 1.1 ± 0.3 4 yrs 1.2 ± 0.3 change no data Placebo: Baseline 1.1 ± 0.3 4 yrs 1.1 ± 0.3 change no data	Simvastatin: Baseline 1.9 ± 1.0 4 yrs 1.7 ± 0.8 change Placebo: Baseline 1.8 ± 0.9 4 yrs 1.9 ± 0.9 change	
MacMahon et al, 1998	Pravastatin 40 mg/day Placebo (n= not stated, assumed equal split; 261) Once daily evening	mmol/L	Pravastatin: Baseline 5.6 ± SE 0.05 3 yrs 4.5 ± SE 0.06 change no data Placebo: Baseline 5.7 ± SE 0.05 3 yrs 5.6 ± SE 0.05 change no data	Pravastatin: Baseline 3.9 ± SE 0.04 3 yrs 2.8 ± SE 0.05 change no data Placebo: Baseline 3.9 ≠ SE 0.05 3 yrs 3.8 ±SE 0.05 change no data	Pravastatin: Baseline 1.0 ± SE 0.01 3 yrs 0.1 ± SE 0.02 change no data Placebo: Baseline 0.9 ± SE 0.01 3 yrs 0.9 ± SE 0.02 change no data	Pravastatin: Baseline 1.8 ± SE 0.06 3 yrs 1.6 ± SE 0.06 change no data Placebo: Baseline 1.7 ± 0.04 3 yrs 1.7 ± 0.07 change no data	Pravastatin significantly more effective than placebo at changing total cholesterol, LDL (p<0.0001), HDL (p<0.001), & triglycerides (p<0.002) at yr 1 & yr 3
Maggi et al, 1994	Simvastatin 20 mg/day (n =20) Placebo (n =20) Bezfibrate 400 mg (n=21)	mg/dL	Simvastatin: Baseline 264 ± 31 6 mths 212 ± 24 change no data Bezfibrate: Baseline 260 ± 33 6 mths 220 ± 19 change no data Placebo: Baseline 266 ± 29 6 mths 262 ± 26 change no data	Simvastatin: Baseline 193 ± 34 6 mths 139 ± 30 change no data Bezfibrate: Baseline 184 ± 30 6 mths 147 ± 20 change no data Placebo: Baseline 198 ± 25 6 mths 191 ± 28 change no data	Simvastatin: Baseline 52 ± 11 6 mths 54 ± 13 change no data Bezfibrate: Baseline 57 ± 12 6 mths 64 ± 12 change no data Placebo: Baseline 49 ± 8 6 mths 49 ± 10 change no data	Simvastatin: Baseline 142 ± 79 6 mths 145 ± 90 change no data Bezfibrate: Baseline 124 ± 79 6 mths 84 ± 38 change no data Placebo: Baseline 121 ± 45 6 mths 148 ± 75 change no data	Simvastatin & bezfibrate significantly more effective than placebo for total cholesterol & LDL(p<0.01). Bezfibrate also significantly more effective than placebo at changing triglycerides & HDL (p<0.01).

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Mercuri et al, 1996	Pravastatin 40 mg once daily (n= 151) Placebo (n= 154)	mmol/L	Pravastatin: Baseline 6.7 ± SD 0.6 3 yrs no data change -1.0± SE0.1 Placebo: Baseline 6.8 ± 0.6 3 yrs no data change +0.2 ± SE 0.1	Pravastatin: Baseline 4.7 ± SD 0.5 3 yrs no data change -1.0 ± SE 0.1 Placebo: Baseline 4.7 ± 0.5 3 yrs no data change +0.1 ± SE 0.1	Pravastatin: Baseline 1.35 ± SD 0.3 3 yrs no data change +0.1 ± SE 0.02 Placebo: Baseline 1.38 ± SD 0.3 3 yrs no data change 0 ± SE 0.02	Pravastatin: Baseline 1.6 ± SD 0.5 3 yrs no data change 0 ± SE 0 Placebo: Baseline 1.6 ± 0.6 3 yrs no data change 0 ± SE 0	
Morgan et al, 1990	Simvastatin 10-40 mg (n=25) Placebo (n=25) Initial 10 mg/day dose given once in evening for 6 wks. Doubled at 6 & 10 wks if total cholesterol >4.5 mmol/L Dose increases: 10 mg 3/24 20 mg 6/24 40 mg 15/24	mmol/L	Simvastatin: Baseline 7.1 no SD; 18 wks 4.7 no SD Placebo: Baseline 7.2 no SD; 18 wks 6.7 no SD	Simvastatin: Baseline 4.7 no SD; 18 wks 2.5 no SD Placebo: Baseline 4.6 no SD; 18 wks 4.1 no SD	Simvastatin: Baseline 1.11 no SD; 18 wks 1.18 no SD Placebo: Baseline 1.0 no SD; 18 wks 1.06 no SD	Simvastatin: Baseline 2.7 no SD; 18 wks 2.2 no SD Placebo: Baseline 3.2 no SD; 18 wks 3.3 no SD	Significant reduction in total cholesterol ($p<0.01$) and triglycerides. Significant increase in HDL(<0.01)

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Morris et al, 1996	Pravastatin (n= 45) Placebo (n= 53)	mmol/L	Pravastatin: Baseline 5.9 (95% CI 5.6 - 6.2) 26 wks 5.5 (95% CI 5.2 - 5.8) change no data Placebo: Baseline 6.1 (95%CI 6.0 - 6.4) 26 wks 6.1 ± (95%CI 5.9 - 6.4) change no data	Pravastatin: Baseline 3.9 (95% CI 3.7 - 4.2) 26 wks 3.5 6.1 (95% CI 3.2 - 3.8) change no data Placebo: Baseline 4.2 (95% CI 4.0 - 4.5) 26 wks 4.2 (95% CI 3.9 - 4.4) change no data	Pravastatin: Baseline 1.7 (95% CI 1.4 - 2.1) 26 wks 1.7 (95% CI 1.5 - 2.0) change no data Placebo: Baseline 1.8 (95% CI 1.5 - 2.2) 26 wks 1.7 (95% CI 1.5 - 2.0) change no data	Pravastatin: Baseline 1.1 (95% CI 1.0 - 1.2) 26 wks 1.2 (95% CI 1.1 - 1.2) change no data Placebo: Baseline 1.1 (95% CI 1.0 - 1.2) 26 wks 1.1 (95% CI 1.0 - 1.2) change no data	
MRC/BHF Heart Protection Study Collaborative Group	Simvastatin 40 mg (n=10269) Placebo (n=10267) Once daily evening	mmol/L	Simvastatin: Baseline 5.8 no SD 36 mths 4.3 no SD change -1.5 (-26%) Placebo: Baseline 5.8 no SD 36 mths 5.8 no SD change none	Simvastatin: Baseline 3.3 no SD 36 mths 2.2 no SD change -1.1 (-33%) Placebo: Baseline 3.4 no SD 36 mths 3.4 no SD change none	Simvastatin: Baseline 1.05 no SD 36 mths 1.09 no SD change +0.04 (4%) Placebo: Baseline 1.05 no SD 36 mths 1.1 no SD change +0.05	Simvastatin: Baseline 2.2 no SD 36 mths 1.8 no SD change -0.4 (-18%) Placebo: Baseline 2.2 no SD 36 mths 2.45 no SD change +0.25 (+11%)	Not stated
Olson et al, 2001	Fluvastatin 40 mg once daily (Immediate release; IR) (n= 174) Fluvastatin 40 mg twice daily (Immediate release; IR) (n=175)	mg/dL	Fluvastatin IR 40 mg once daily: Baseline 289 ± 44 24 wks no data change -17% ± SE 0.9 Fluvastatin IR 40 mg twice daily: Baseline 284 ± 38 24 wks no data change -24% ± 0.9	Fluvastatin IR 40 mg once daily: Baseline 203 ± 43 24 wks no data change -24% ± SE 1.2 Fluvastatin IR 40 mg twice daily: Baseline 199 ± 36 24 wks no data change -34 ± SE 1.2	Fluvastatin IR 40 mg once daily: Baseline 55 ± 12 24 wks no data change +7% ± SE 1.3 Fluvastatin IR 40 mg twice daily: Baseline 52 ± 11 24 wks no data change +8% ± SE 1.3	Fluvastatin IR 40 mg once daily: Baseline 158 ± 57 24 wks no data change -7% ± SE 2.5 Fluvastatin IR 40 mg twice daily: Baseline 165 ± 68 24 wks no data change -14% ± SE 2.5	

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Olson et al. 2001 (Abstract)	Rosuvastatin 5 mg (n=138) Rosuvastatin 10 mg (n=134) Atorvastatin 10 mg (n=140)	mmol/L	Atorvastatin 10 mg: Baseline 7.08; 12 / 52 wks no data % change (SE) 12 wks -28.1 (0.9) Rosuvastatin 5 mg: Baseline 7.07 12 / 52 wks no data % change (SE) 12 wks -31.9 (1.0) Rosuvastatin 10 mg: Baseline 7.00 12 / 52 wks no data % change (SE) 12 wks -35.3 (1.0)	Atorvastatin 10 mg: Baseline 4.86 12 /52 wks no data % change (SE) 12 wks -39.5 (1.2); 52 wks -44.3% (1.1) Rosuvastatin 5 mg: Baseline 4.86 12 /52 wks no data % change (SE) 12 wks -45.6 (1.3); 52 wks -47.6% (1.2) Rosuvastatin 10 mg: 12 /52 wks no data 12 wks no data % change (SE) 12 wks -50.1 (1.3); 52 wks -53.2% (1.2)	Atorvastatin 10 mg: Baseline 1.39 12 / 52 wks no data % change (SE) 12 wks 6.2 (1.2); 52 wks -0.6% (1.3) Rosuvastatin 5 mg: Baseline 1.41 12 / 52 wks no data % change (SE) 12 wks 6.2 (1.3); 52 wks 1.9% (1.3) Rosuvastatin 10 mg: Baseline 1.44 12 / 52 wks no data % change (SE) 12 wks 8.0 (1.3); 52 wks (3.5% (1.4)	Atorvastatin 10 mg: Baseline 1.81 12 / 52 wks no data % change (SE) -16.2 (2.4); 52 wks -18.7% (2.4) Rosuvastatin 5 mg: Baseline 1.76 12 / 52 wks no data % change (SE) -15.1 (2.5); 52 wks -_9.6% (2.4) Rosuvastatin 10 mg: Baseline 1.65 12 / 52 wks no data % change (SE) -19.1 (2.5); 52 wks -21.4% (2.6)	Atorvastatin 10 mg: (number = population) High risk 105, 50.5% Other 34, 70.6% All patients 139, 55.4% Rosuvastatin 5 mg: High risk 107, 71.0% Other 28, 89.3% All patients 135, 74.8% Rosuvastatin 10 mg: High risk 92, 85.9% Other 40, 87.5% All patients 132, 86.4%
Ose et al, 1999	Cerivastatin 0.2 mg (n=162) Cerivastatin 0.4 mg (n=332) Given once daily (bed time)	mg/dL	Cerivastatin 0.2 mg: Baseline 264 ± 2.9 (6.82 ± 0.07) 24 wks no data change -20.6% ± 0.7 Cerivastatin 0.4 mg: Baseline 264 ± 2.1 (6.84 ± 0.05) 24 wks no data change -25.6% ± 0.5	Cerivastatin 0.2 mg: Baseline 181 ± 2.5 (4.7 ±0.06) 24 wks no data change -30.3% ± 1.0 Cerivastatin 0.4 mg: Baseline180 ± 1.8 (4.7 ± 0.05) 24 wks no data change -37.9% ± 0.7	Cerivastatin 0.2 mg: Baseline 52.7 ± 1.2 (1.4 ± 0.03) 24 wks no data change +7.4% ± 1.1 Cerivastatin 0.4 mg: Baseline 53.2 ± 0.9 (1.4 ± 0.02) 24 wks no data change +8.4% ± 0.8	Cerivastatin 0.2 mg: Baseline 152 ± 4.9 (1.7 ± 0.06) 24 wks no data change -11.5% ± 2.2 Cerivastatin 0.4 mg: Baseline 151 ± 3.6 (1.7 ± 0.04) 24 wks no data change -11.1% ± 1.6	There was no significant difference between doses of cerivastatin for triglycerides or HDL cholesterol. Cerivastatin 0.4 mg was significantly more effectve than 0.2 mg at changing total & LDL cholesterol.

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Ose et al, 2000	Simvastatin 40 mg (n= 436) Simvastatin 80 mg (n= 669)	mmol/L	Simvastatin 40 mg: Baseline 8.1 ± 1.6 24 wks 5.6 ± 1.2 change no data Simvastatin 80 mg: Baseline 7.9 ± 1.5 24 wks 5.1 ± 1.1 change no data	Simvastatin 40 mg: Baseline 5.9 ± 1.6 24 wks 3.5 ± 1.1 change -41% (-42 to -39) Simvastatin 80 mg: Baseline 5.8 ± 1.5 24 wks 3.1 ± 1.1 change -47% (-48 to -46)	Simvastatin 40 mg: Baseline 1.3 ± 0.3 24 wks 1.4 ± 0.3 change +8.5% (7.2 to 9.8) Simvastatin 80 mg: Baseline 1.3 ± 0.3 24 wks 1.3 ± 0.3 change +8.1% (7.1 to 9.0)	Simvastatin 40 mg: Baseline 1.8 ± 0.9 24 wks 1.4 ± 0.8 change -18% (-21 to -15) Simvastatin 80 mg: Baseline 1.8 ± 1.0 24 wks 1.3 ± 0.6 change -24% (-26 to -23)	Simvastatin 40 mg was significantly more effective than 80 mg at changing total cholesterol, LDL and triglycerides but not HDL.
Paoletti et al, 2001	Rosuvastatin 5 mg (n=120) Rosuvastatin 10 mg (n= 115) Pravastatin 20 mg (n= 137) Simvastatin 20 mg (n= 120)	mmol/L	Rosuvastatin 5 mg: Baseline 7.1 ± 0.6 12 wks no data change -30% ± 0.9 Rosuvastatin 10 mg: Baseline 7.0 ± 0.6 12 wks no data change -34% ± 1.0 Pravastatin 20 mg: Baseline 7.1 ± 0.6 12 wks no data change -20% ± 0.9 Simvastatin 20 mg: Baseline 7.1 ± 0.7 12 wks no data change -26% ± 0.9	Rosuvastatin 5 mg: Baseline 4.9 ± 0.5 12 wks no data change -42% ± 1.3 Rosuvastatin 10 mg: Baseline 4.8 ± 0.5 12 wks no data change -49% ± 1.3 Pravastatin 20 mg: Baseline 4.9 ± 0.5 12 wks no data change -28% ± 1.2 Simvastatin 20 mg: Baseline 4.9 ± 0.6 12 wks no data change -35% ± 1.2	Rosuvastatin 5 mg: Baseline 1.3 ± 0.3 12 wks no data change +6.0% ± 1.2 Rosuvastatin 10 mg: Baseline 1.4 ± 0.3 12 wks no data change +7.0% ± 1.3 Pravastatin 20 mg: Baseline 1.4 ± 0.3 12 wks no data change +4.0% ± 1.2 Simvastatin 20 mg: Baseline 1.4 ± 0.3 12 wks no data change +4.0% ± 1.2	Rosuvastatin 5 mg: Baseline 1.9 ± 0.7 12 wks no data change -12% ± 2.9 Rosuvastatin 10 mg: Baseline 1.8 ± 0.7 12 wks no data change -18% ± 3.0 Pravastatin 20 mg: Baseline 1.8 ± 0.7 12 wks no data change -13% ± 2.7 Simvastatin20 mg: Baseline 1.8 ± 0.7 12 wks no data change -14% ± 2.8	Rosuvastatin 5 mg significantly more effective than pravastatin ($p<0.001$) or simvastatin ($p<0.005$) at reducing total cholesterol & LDL. Rosuvastatin 10 mg significantly more effective than pravastatin or simvastatin at reducing total cholesterol & LDL ($p<0.001$).

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Pauciullo et al, 2000	Fluvastatin 40 mg (n= 80) Evening Bezfibrate 400 mg (n= 86) Given twice daily	mg/dL	Fluvastatin: Baseline 282 ± 39 24 wks no data change -17% (95% CI -20 to -15) Bezfibrate: Baseline 274 ± 36 24 wks no data change -10% (95% CI -12 to -7.2)	Fluvastatin: Baseline 189 ± 35 24 wks no data change -23% (95% CI -26 to -18) Bezfibrate: Baseline 179 ± 32 24 wks no data change -10% (95% CI -13 to -6.2)	Fluvastatin: Baseline 40 ± 8 24 wks no data change 0.3% (95% CI -3.8 to 4.5) Bezfibrate: Baseline 43 ± 10 24 wks no data change 17% (95% CI13 to 21)	Fluvastatin: Baseline 263 ± 64 24 wks no data change -6% (95% CI-14 to 2.3) Bezfibrate: Baseline 257 ± 65 24 wks no data change -25% (95% CI-33 to -17)	Fluvastatin was signifcantly better at changing LDL & total cholesterol than bezfibrate (p<0.001) Bezfibrate was signifncatly better at changing HDL & triglycerides than fluvastatin (p<0.001)
Pedersen, 1998	Simvastatin 20 mg mg/day (n=2221) Placebo (n=2223) Titration to 40 mg at 12 or 24 wk in patients who did not reach target total cholesterol of 3.0-5.2 mmol/L after 6-12 wk Daily dose taken: 10 mg 2 pts (0.1%) 20 mg 62.9% 40 mg 37%	mmol/L	Simvastatin: Baseline 6.5 ± 0.7 6 wk 4.5 % change -25% Placebo: Baseline 6.8 ± 0.7 6 wk no data % change +1%	Simvastatin: Baseline 4.9 ± 0.7 6 wk no data % change -35% Placebo: Baseline 4.9 ± 0.7 6 wk no data % change +1%	Simvastatin: Baseline 1.2 ± 0.3 6 wk no data % change +8% Placebo: Baseline 1.2 ± 0.3 6 wk no data % change +1%	Simvastatin: Baseline 1.5 ± 0.5 6 wk no data % change -10% Placebo: Baseline 1.5 ± 0.5 6 wk no data % change +7%	
Pitt et al, 1993	Pravastatin 40 mg (n=206) Placebo (n= 202) Once daily in evening Mean daily dose 39 mg	mmol/L / mg/dL	Pravastatin: Baseline 5.97 no SD 3 yrs no data change -19% Placebo: Baseline 229 mg/dL 3 yrs no data change +2%	Pravastatin: Baseline 4.24 no SD 3 yrs no data change -28% Placebo: Baseline 162 mg/dL 3 yrs no data change +1%	Pravastatin: Baseline 1.06 no SD 3 yrs no data change +7% Placebo: Baseline 41 mg/dL 3 yrs no data change +2%	Pravastatin: Baseline 1.87 no SD 3 yrs no data change -8% Placebo: Baseline 165 mg/dL 3 yrs no data change +9%	Pravastatin was significantly more effective than placebo at changing all parameters (p<0.001)

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Reigger et al, 1999	Fluvastatin 40 mg (n=187) 85 pts had dose doubled Placebo (n=178)	mg/dL	Fluvastatin: Baseline 289 ± 46; 52 wk no data; % change -17.4% Placebo: Baseline 284 ± 39; 52 wk no data; % change -4.9%	Fluvastatin: Baseline 198 ± 39; 52 wk no data; % change no data Placebo: Baseline 193 ± 36; 52 wk no data; % change no data	Fluvastatin: Baseline 53 ± 16; 52 wk no data; % change no data Placebo: Baseline 56 ± 16; 52 wk no data; % change no data	Fluvastatin: Baseline 189 ± 92; 52 wk no data; % change no data Placebo: Baseline 183 ± 81; 52 wk no data; % change no data	Significantly greater reduction in total, LDL cholesterol than with placebo (p<0.0001. No significant difference for triglycerides.
Ritter et al, 1993	Pravastatin 20 mg (n= 79) Evening Dose doubled at 14 wks if total cholesterol not reduced by 15% or above 5.2 mmol/L (n= 12) Placebo (n=75) Dose doubled in 58 patients after 14 wks	mmol/L	Pravastatin: Baseline 6.8 (95% CI 5.4 to 8.8) 26 wks 5.4 (95% CI 4.0 to 6.8) change Placebo: Baseline 6.7 (95% CI 4.9 to 8.4) 26 wks 6.6 (95% CI 5.1 to 8.4) change	Pravastatin: Baseline 4.9 (95% CI 3.0 to 6.9) 26 wks 3.3 (95% CI 1.1 to 4.9) change Placebo: Baseline 4.7 (95% CI 3.3 to 6.6) 26 wks 4.4 (95% CI 3.0 to 8.4) change	Pravastatin: Baseline 1.1 (95% CI 0.6 to 5.3) 26 wks 1.3 (95% CI 0.7 to 5.9 change Placebo: Baseline 1.0 (95% CI 0.6 to 2.5) 26 wks 1.2 (95% CI 0.7 to 2.5) change	Pravastatin: Baseline 1.6 (95% CI 0.6 to 5.3) 26 wks 1.4 (95% CI 0.5 to 3.6) change Placebo: Baseline 1.8 (95% CI 0.7 to 5.5) 26 wks 1.7 (95% CI 0.5 to 5.0) change	Significantly greater change in total cholesterol, LDL & triglycerides with pravastatin compared with placebo (p<0.001) No significant difference between groups for HDL
Rubenfire et al, 1991	Pravastatin 20 mg (n= 57) Placebo (n= 25) Dose increased to 40 mg at end of wk 8 in all patients	mmol/L	Pravastatin: Baseline 6.9 ± 0.9 16 wks 5.3 (no SD) change -23% Placebo: Baseline 6.8 ± 0.8 16 wks 6.8 (no SD) change 0%	Pravastatin: Baseline 5.2 ± 0.9 16 wks 3.6 (no SD) change -31% Placebo: Baseline 5.0 ± 0.9 16 wks 5.1 (no SD) change +1%	Pravastatin: Baseline 1.1 ± 0.3 16 wks 1.2 (no SD) change +9% Placebo: Baseline 1.1 ± 0.4 16 wks 1.2 (no SD) change +7%	Pravastatin: Baseline 1.6 ± 0.5 16 wks 1.3 (no SD) change -20% Placebo: Baseline 1.7 ± 0.6 16 wks 1.4 (no SD) change -18%	Significant change from baseline with pravastatin for total cholesterol, LDL & HDL (p<0.01) and triglyceride (p<0.05) Significantly greater increase in HDL with pravastatin than with placebo

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Sacks et al, 1996	Pravastatin 40 mg (n= 2081) Placebo (n= 2078) Once daily, evening	mg/dL	Pravastatin: Baseline 209 ± 17 5 yrs no data change no data Placebo: Baseline 209 ± 17 5 yrs no data change no data	Pravastatin: Baseline 139 ± 15 (3.6 mmol/L) 5 yrs 98 (2.5 mmol/L) change -32% Placebo: Baseline 139 ± 15 5 yrs no data change -4%	Pravastatin: Baseline 39 ± 9 5 yrs no data change no data Placebo: Baseline 39 ± 9 5 yrs no data change no data	Pravastatin: Baseline 155 ± 61 5 yrs no data change no data Placebo: Baseline 155 ± 61 5 yrs no data change no data	Pravastatin was significantly more effective than placebo at changing total cholesterol, LDL, HDL and triglycerides ($p<0.001$)
Saito et al, 1991	Simvastatin 2.5 mg in morning (n=30) Simvastatin 2.5 mg in evening (n=28) Simvastatin 5 mg in morning (n=32) Simvastatin 5 mg in evening (n=29) Placebo (n=31)	md/dL	Simvastatin 2.5 mg (am): Baseline 273 ± 340; during treatment 242 ± 37; % change -10.9 Simvastatin 2.5 mg (pm): Baseline 275 ± 37; during treatment 233 ± 45; % change -15.4 Simvastatin 5 mg mg (am): Baseline 277 ± 50; during treatment 238 ± 45; % change -13.7 Simvastatin 5 mg (pm): Baseline 289 ± 47; during treatment 228 ± 39; % change -3.8 Placebo: Baseline 285 ± 45; during treatment 286 ± 41; % change 0.3	Simvastatin 2.5 mg (am): Baseline 183 ± 47; 12 wks 149 ± 35; % change -15.1 Simvastatin 2.5 mg (pm): Baseline 196 ± 37; 12 wks 156 ± 43; % change -21.1 Simvastatin 5 mg mg (am): Baseline 194 ± 48; 12 wks 153 ± 47; % change -22.0 Simvastatin 5 mg (pm): Baseline 204 ± 52; 12 wks 141 ± 32; % change -30 Placebo: Baseline 200 ± 54; 12 wks 200 ± 56; % change 0.5	Simvastatin 2.5 mg (am): Baseline 54 ± 25; during treatment 58 ± 22; % change 10.6 Simvastatin 2.5 mg (pm): Baseline 47 ± 15; during treatment 49 ± 15; % change 4.6 Simvastatin 5 mg mg (am): Baseline 53 ± 18; during treatment 54 ± 18; % change 2.8 Simvastatin 5 mg (pm): Baseline 53 ± 13; during treatment 56 ± 14; % change 5.4 Placebo: Baseline 50 ± 14; during treatment 51 ± 16; % change 2.9	Simvastatin 2.5 mg (am): Baseline 180 ± 105; during treatment 153 ± 76; % change -7.5 Simvastatin 2.5 mg (pm): Baseline 160 ± 72; during treatment 155 ± 78; % change -1.2 Simvastatin 5 mg mg (am): Baseline 152 ± 77; during treatment 146 ± 76; % change 1.7 Simvastatin 5 mg (pm): Baseline 156 ± 69; during treatment 134 ± 53; % change -4.9 Placebo: Baseline 178 ± 125; during treatment 177 ± 124; % change 5.3	Significantly greater reduction in total cholesterol & LDL with evening dose of 2.5 or 5 mg simvastatin than with morning dose ($p<0.05$). 5 mg was significantly better at reducing total cholesterol than 2.5 mg ($p<0.05$). No significant difference from basleline for any group for triglycerides. Significant difference from baseline in HDL with all doses of simvastatin except 5 mg given in the morning ($p<0.05$) No significant difference between simvastatin & placebo.

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Salonen et al, 1995	Pravastatin 40 mg Placebo	mmol/L	Pravastatin 40 mg: Baseline 6.7 ± 0.6 3 yrs 5.2 ± 0.6 % change -21.0 Placebo: Baseline 6.7 ± 0.6 3 yrs 6.7 ± 0.7 % change -0.9	Pravastatin 40 mg: Baseline 4.8 ± 0.6 3 yrs 3.4 ± 0.7 % change -27.4 Placebo: Baseline 4.8 ± 0.6 3 yrs 5.0 ± 0.7 % change 1.5		Pravastatin 40 mg: Baseline 1.7 ± 0.8 3 yrs 1.5 ± 0.7 % change -7.6 Placebo: Baseline 1.7 ±0.8 3 yrs 1.7 ± 0.8 % change 4.7	
Santinga et al, 1994	Pravastatin (n= 94) Placebo (n= 48)	mg/dL	Pravastatin: Baseline 272 ±28 16 wks 214 ± 31 change -22 (95% CI -24 to -20) Placebo: Baseline 279 ±43 16 wks 282 ± 49 change +0.9 (95% CI -2.3 to 4.3)	Pravastatin: Baseline 198 ± 24 16 wks 139 ± 24 change -31% (95% CI -33 to -29) Placebo: Baseline 208 ± 41 16 wks 210 ± 49 change +0.6 (95% CI-3.7 to 5.2)	Pravastatin: Baseline 50.2 ± 13 16 wks 55.4 ± 14 change -22% (95% CI -24 to -20) Placebo: Baseline 46 ± 11 16 wks 55 ± 14 change +11% (95% CI 8.5 to 14)	Pravastatin: Baseline 144 ± 42 16 wks 122 ± 39 change -17% (95% CI -21 to -12) Placebo: Baseline 155 ± 46 16 wks 152 ± 70 change -4% (95% CI -11 to -3.2)	Significant change from baseline for LDL, HDL, total cholesterol & triglycerides (p<0.001). Pravastatin significantly more effective than placebo for LDL, total cholesterol (p<0.001), HDL (p<0.01).
Seed et al, 1999	Simvastatin 20 mg evening (n= 194) Pravastatin 40 mg evening (n= 193)	mg/dL	No dispersion (SD/SE provided) Simvastatin: Baseline 7.5 12 wks 5.5 change -26% Pravastatin: Baseline 7.4 12 wks 6.0 change -19%	No dispersion (SD/SE provided) Simvastatin: Baseline 5.4 12 wks 3.5 change -34% Pravastatin: Baseline 5.3 12 wks 3.9 change -26%	No dispersion (SD/SE provided) Simvastatin: Baseline 1.15 12 wks 1.2s change +12% Pravastatin: Baseline 1.14 12 wks 1.22 change +12%	No dispersion (SD/SE provided) Simvastatin: Baseline 2.0 12 wks 1.5 change -22% Pravastatin: Baseline 2.0 12 wks 1.6 change -16%	Significant change from baseline for all lipid parameters with both treatments (p<0.001) Simvastatin significantly more effective than pravastatin for changing total & LDL cholesterol (p<0.001)

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Sigurdsson et al, 1996	Simvastatin (n= 56) Fluvastatin (n= 57) Dose doubled at wk 10 if 6 wk reading of total cholesterol>5.2 mmol/L	mmol/L	Simvastatin: Baseline 6.7 ±0.8 16 wks no data change -31% ± 10 Fluvastatin: Baseline 6.7 ± 0.7 16 wks no data change -20% ± 9.3	Simvastatin: Baseline 4.8 ± 0.8 16 wks no data change -40% ± 15 Fluvastatin: Baseline 4.9 ± 0.7 16 wks no data change -25% ± 11	Simvastatin: Baseline 1.2 ± 0.3 16 wks no data change 11% ± 17 Fluvastatin: Baseline 1.1 ± 0.3 16 wks no data change 8.8 ± 18	Simvastatin: Baseline 1.3 ± no SD 16 wks no data change -23% ± no SD Fluvastatin: Baseline 1.4 ± no SD 16 wks no data change -23% ± no SD	
Simvastatin Pravastatin Study Group, 1993	Simvastatin 10-40 mg (n= 275) Pravastatin 10-40 mg (n=275) Initial daily dose doubled after 6 wks & again after 12 wks if LDL remained >130 mg/dL Mean daily dose: Sim & Prav 27 mg/day. Number taking: Sim 10 mg 82 (30%) Sim 20 mg 60 (22%) Sim 40 mg 133 (48%) Prav 10 mg 39 (14%) Prav 20 mg 56 (20%) Prav 40 mg 180 (66%)	mg/dL	Simvastatin: Baseline 301 ± 63 18 wks no data change -23 (-14%) Pravastatin: Baseline 307 ± 70 18 wks no data change -15 (-14%)	Simvastatin: Baseline 207 ± 67 18 wks no data change -30 (-23%) Pravastatin: Baseline 212 ± 73 18 wks no data change -19 (-20%)	Simvastatin: Baseline 49 ± 13 18 wks no data change +9 (+20%) Pravastatin: Baseline 52 ± 14 18 wks no data change +5 (+22%)	Simvastatin: Baseline 141 ± 91 18 wks no data change -16 (-39%) Pravastatin: Baseline 139 ± 100 18 wks no data change -10 (-35%)	Simvastatin significantly more effective than pravastatin
Steinhagen-Thiessen, 1994	Simvastatin 5-10 mg (n= 143) Initial 5 mg dose increased to 10 mg after 6 wks Pravastatin 10 mg (n= 138) Dose remained constant throughout	mmol/L	Simvastatin: Baseline 6.6 no SD 12 wks 5.4 no SD change -19% ± 12 Pravastatin: Baseline 6.6 no SD 12 wks 5.9 no SD change -11% ± 12	Simvastatin: Baseline 4.6 no SD 12 wks 3.3 no SD change -27% ± 18 Pravastatin: Baseline 4.5 no SD 12 wks 3.7 no SD change -17% ± 18	Simvastatin: Baseline 1.3 no SD 12 wks 1.4 no SD change +8% ± 26 Pravastatin: Baseline 1.3 no SD 12 wks 1.4 no SD change +8% ± 23	Simvastatin: Baseline 1.6 no SD 12 wks 1.3 no SD change -10% no SD Pravastatin: Baseline 1.5 no SD 12 wks 1.4 no SD change -4% no SD	All parameteres significantly changed from baseline except triglycerides with pravastatin. Pravastatin significantly more effective than placebo for changing total, LDL & HDL cholesterol (p<0.01)

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Steinmetz et al, 1996	Simvastatin 20 mg (n= 66) Micronised fenofibrate 200 mg (n= 67) Once daily	mg/dL	Simvastatin: Baseline 292 ± 61 12 wks no data change -24.7% Fenofibrate: Baseline 294 ± 56 12 wks no data change -19.5%	Simvastatin: Baseline 207 ± 53 12 wks no data change -34.95% Fenofibrate: Baseline 213 ± 53 12 wks no data change -20.85%	Simvastatin: Baseline 36 ± 12 12 wks no data change +15.0% Fenofibrate: Baseline 37 ± 13 12 wks no data change +18.5%	Simvastatin: Baseline 257 ± 203 12 wks no data change -16.5% Fenofibrate: Baseline 215 ± 142 12 wks no data change -41.4%	Simvastatin was significantly better than fenofibrate at reducing total cholesterol. Fenofibrate was significantly better than simvastatin at reducing LDL & triglycerides and at increasing HDL.
Sweany et al, 1993	Simvastatin 10 mg (n=275) Pravastatin 10 mg (n=275) Evening Dose titration from 10 mg to 40 mg/day at 6 & 12 wks if LDL >130 mg/dL (3.4 mmol/L)	mg/dL	Simvastatin: Baseline 301 ± 63 18 wks no data change -27% ± 11 Pravastatin: Baseline 307 ± 70 18 wks no data change -19% ± 14	Simvastatin: Baseline 207 ± 67 18 wks no data change -38% ± 17 Pravastatin: Baseline 212 ± 73 18 wks no data change -26% ± 20	Simvastatin: Baseline 49 ±13 18 wks no data change +15% ±21 Pravastatin: Baseline 52 ± 14 18 wks no data change +12% ± 22	Simvastatin: Baseline 141 ± 91 18 wks no data change -18% ± 32 Pravastatin: Baseline 139 ± 100 18 wks no data change -14% ± 33	Simvastatin significantly better at reducing total cholesterol & LDL than pravastatin ($p<0.01$).
Teo et al, 1997	Simvastatin 10-40 mg (n= 230) Placebo (n= 230) Once daily evening Dose titration according to LDL levels Average daily dose: 28.5 mg ± 13.0	mmol/L	Simvastatin: Baseline: 5.2 ± 0.6 3 yrs 4.1 ± 0.6 change -1.09 (-20.6%) Placebo: Baseline: 5.1 ± 0.6 3 yrs 5.3 ± 0.7 change +0.15 (+3.3%)	Simvastatin: Baseline: 3.4 ± 0.6 3 yrs 2.3 ± 0.5 change -1.06 (-30.5%) Placebo: Baseline: 3.3 ± 0.6 3 yrs 3.4 ± 0.5 change +0.08 (+3.5%)	Simvastatin: Baseline: 0.99 ± 0.2 3 yrs 1.1 ± 0.2 change +0.07 (+8.4%) Placebo: Baseline: 0.97 ± 0.3 3 yrs 1.0 ± 0.3 change +0.02 (+3.4%)	Simvastatin: Baseline: 1.9 ± 0.8 3 yrs 1.6 ± 0.7 change -0.23 (-9.7%) Placebo: Baseline: 1.8 ± 0.7 3 yrs 1.9 ± 0.9 change 0.13 (-8.6%)	Simvastatin significantly more effective than placebo at changing total cholesterol, LDL, triglycerides ($p<0.001$) and HDL ($p<0.05$)

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
The Lovastatin Pravastatin Study Group, 1993	Lovastatin (n= 339) Pravastatin (n= 333) Dose titration from 20 mg to 80 mg/day (at 6 & 12 wks) in all patients	mg/dL	Lovastatin: Baseline 287 ± 45 18 wks no data change -28% ± 13 Pravastatin: Baseline 288 ± 47 18 wks no data change -19% ± 12	Lovastatin: Baseline 194 ± 48 18 wks no data change -39% ± 18 Pravastatin: Baseline 196 ± 49 18 wks no data change -27% ± 16	Lovastatin: Baseline 51 ± 16 18 wks no data change +19% ± 41 Pravastatin: Baseline 49 ± 16 18 wks no data change +16% ± 37	Lovastatin: Baseline 145 ± 80 18 wks no data change -22% ± 35 Pravastatin: Baseline 140 ± 206 18 wks no data change -15% ± 34	Significant change from baseline to 18 wks with lovastatin for total cholesterol & LDL ($p<0.05$). Reduction in triglycerides significantly better with lovastatin than with pravastatin at 18 wks ($p<0.05$)
The Lovastatin Study Group, 1990	Lovastatin 40 mg morning (n= 49) Lovastatin 40 mg evening (n= 47) Lovastatin 40 mg twice daily (n= 48) Lovastatin 80 mg evening (n= 49) Probucol 500 mg given twice daily (n= 97). Daily dose 1000 mg	mmol/L	Lovastatin 40 mg morning: Baseline 9.5 no SD 14 wks no data change -20% Lovastatin: 40 mg evening Baseline 9.6 no SD 14 wks no data change -25% Lovastatin 40 mg twice: Baseline 9.4 no SD 14 wks no data change -33% Lovastatin 80 mg evening: Baseline 9.8 no SD 14 wks no data change -30% Probucol: Baseline 9.5 no SD 14 wks no data change -10%	Lovastatin 40 mg morning: Baseline 7.5 no SD 14 wks no data change -25% Lovastatin: 40 mg evening Baseline 7.7 no SD 14 wks no data change -32% Lovastatin 40 mg twice: Baseline 7.8 no SD 14 wks no data change -39% Lovastatin 80 mg evening: Baseline 7.6 no SD 14 wks no data change -36% Probucol: Baseline 7.6 no SD 14 wks no data change -8%	Lovastatin 40 mg morning: Baseline 1.1 no SD 14 wks no data change +11% Lovastatin: 40 mg evening Baseline 1.3 no SD 14 wks no data change +9% Lovastatin 40 mg twice: Baseline 1.1 no SD 14 wks no data change +11% Lovastatin 80 mg evening: Baseline 1.2 no SD 14 wks no data change +10% Probucol: Baseline 1.1 no SD 14 wks no data change -23%	Lovastatin 40 mg morning: Baseline 1.6 no SD 14 wks change Lovastatin: 40 mg evening Baseline 1.3 no SD 14 wks change Lovastatin 40 mg twice: Baseline 1.6 no SD 14 wks change Lovastatin 80 mg evening: Baseline 1.5 no SD 14 wks change Probucol: Baseline 1.8 no SD 14 wks change	

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
The Pravastatin Multinational Study Group for Cardiac Risk Patients, 1993	Pravastatin 20 mg evening (n= 530) Placebo (n= 532) Dose doubled at 13 wks if total cholesterol not reduced by 15% or above 5.2 mmol/L (n= 69; 31%)	mmol/L	Pravastatin (n=521): Baseline 6.8 ± 0.8 26 wks 5.6 ± 0.8 change -19% Placebo (n= 529): Baseline 6.9 ± 0.8 26 wks 6.9 ± 0.9 change -0.2%	Pravastatin (n=499): Baseline 26 wks change Placebo (n= 510): Baseline 26 wks change	Pravastatin (n= 500): Baseline 1.1 ± 0.4 26 wks 1.2 ± 0.4 change +7.9% Placebo (n= 510): Baseline 1.2 ± 0.4 26 wks 1.2 ± 0.4 change +2.6%	Pravastatin (n= 520): Baseline 1.8 ± 0.8 26 wks 1.6 ± 0.7 change -12% Placebo (n=525): Baseline 1.9 ± 0.9 26 wks 1.8 ± 0.9 change -1.1%	Significant change from baseline for total cholesterol, LDL & triglycerides with pravastatin compared with placebo (p<0.001).
Tikkanen et al, 1988	Lovastatin (n= 167) Evening Stratum I: (n=53) 20-40 mg/day Stratum II: n=114) 40-80 mg/day Number titrated to higher dose: Stratum I: 49 Stratum II: 106 Gemfibrozil (n= 167) Stratum I & II: 600 mg given twice daily Stratum I: (n= 56) Stratum II: (n= 111)	mg/dL	Lovastatin Stratum I: Baseline 287 no SD 12 wks no data change -23% Lovastatin Stratum II: Baseline 378 no SD 12 wks no data change -34% Gemfibrozil Stratum I: Baseline 282 no SD 12 wks no data change -11% Gemfibrozil Stratum II: Baseline 365 12 wks no data change -16%	Lovastatin Stratum I: Baseline 202 no SD 12 wks no data change -31% Lovastatin Stratum II: Baseline 293 no SD 12 wks no data change -42% Gemfibrozil Stratum I: Baseline 201 no SD 12 wks no data change -13% Gemfibrozil Stratum II: Baseline 281 no SD 12 wks no data change -18%	Lovastatin Stratum I: Baseline 48 no SD 12 wks no data change +7% Lovastatin Stratum II: Baseline 47 no SD 12 wks no data change +8% Gemfibrozil Stratum I: Baseline 49 no SD 12 wks no data change +18% Gemfibrozil Stratum II: Baseline 52 no SD 12 wks no data change +12%	Lovastatin Stratum I: Baseline 185 no SD 12 wks no data change -13% Lovastatin Stratum II: Baseline 181 no SD 12 wks no data change -14% Gemfibrozil Stratum I: Baseline 170 no SD 12 wks no data change -45% Gemfibrozil Stratum II: Baseline 167 no SD 12 wks no data change -39%	Lovastatin significantly more effective than gemfibrozil for total cholesterol & LDL but significantly less effective for HDL and triglycerides (p<0.01)

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Tikkanen et al, 1989	Simvastatin given once daily in the afternoon Simvastatin 5 mg (stratum I) (n= 68) Simvastatin 10 mg (stratum II) (n= 78) Dose was doubled after 6 wks if LDL >140 mg/dL Gemfibrozil 600 mg twice daily (n= 68) Stratum I: Gemfibrozil 600 mg twice daily (n=75) Stratum II: Daily dose 1200 mg Dose was unchanged throughout	mg/dL	Simvastatin stratum I: Baseline 296 ± no SD 12 wks -21± no SD change -19% ± no SD Simvastatin stratum II: Baseline 347 ± no SD 12 wks -27 ± no SD change no data Gemfibrozil stratum I: Baseline 318 ± no SD 12 wks -15 ± no SD change -14% ± no SD Gemfibrozil stratum II: Baseline 350 ± no SD 12 wks -15 ± no SD change no data	Simvastatin stratum I: Baseline 217 ± no SD 12 wks -26 ± no SD change Simvastatin stratum II: Baseline 265 ± no SD 12 wks -34 ± no SD change no data Gemfibrozil stratum I: Baseline 240 ± no SD 12 wks -18 ± no SD change Gemfibrozil stratum II: Baseline 272 ± no SD 12 wks -17 ± no SD change no data	Simvastatin stratum I: Baseline 46 ± no SD 12 wks +7.0 ± no SD change Simvastatin stratum II: Baseline 49 ± no SD 12 wks +9.1 ± no SD change no data Gemfibrozil stratum I: Baseline 46 ± no SD 12 wks 17 ± no SD change Gemfibrozil stratum II: Baseline 46 ± no SD 12 wks 16 ± no SD change no data	Simvastatin stratum I: Baseline 165 ± no SD 12 wks -10 ± no SD change Simvastatin stratum II: Baseline 151 ± no SD 12 wks -7.1 ± no SD change no data Gemfibrozil stratum I: Baseline 165 ± no SD 12 wks -31 ± no SD change Gemfibrozil stratum II: Baseline 159 ± no SD 12 wks -32 ± no SD change no data	Stratum I (LDL<195 mg/dL): Simvastatin significantly better than gemfibrozil at reducing total & LDL cholesterol (p<0.01). Gemfibrozil significantly better than simvastatin at changing HDL (p<0.05) & triglycerides (p<0.01). Stratum II (LDL>195 mg/dL): Simvastatin significantly better than gemfibrozil at reducing total & LDL cholesterol (p<0.01). Gemfibrozil significantly better than simvastatin at changing HDL & triglycerides (p<0.05).
Valles et al, 1991	Lovastatin Group I 20 mg (n=44) Group II 40 mg (n=42) Given in evening Dose was doubled after 6 wks if total cholesterol > 200 mg/dL Gemfibrozil 1200 mg (600 mg given twice daily) (n= 96) Group I (n=43) Group II (n=53)	mg/dL	Lovastatin Group I: Baseline 274 ± 16 12 wks 218 ± 27 change -20% Lovastatin Group II: Baseline 364 ± 67 12 wks 268 ± 56 change -26% Gemfibrozil Group I: Baseline 270 ± 12 12 wks 250 ± 34 change -8% Gemfibrozil Group II: Baseline 345 ± 53 12 wks 299 ± 59 change -13%	Lovastatin Group I: Baseline 202 ± 18 12 wks 145 ± 23 change -28% Lovastatin Group II: Baseline 284 ± 75 12 wks 189 ± 60 change -33% Gemfibrozil Group I: Baseline 196 ± 16 12 wks 177 ± 31 change -9% Gemfibrozil Group II: Baseline 266 ± 59 12 wks 227 ± 65 change -14%	Lovastatin Group I: Baseline 46 ± 13 12 wks 50 ± 13 change +8% Lovastatin Group II: Baseline 51 = 15 12 wks 54 ± 13 change +6% Gemfibrozil Group I: Baseline 48 ± 12 12 wks 55 ± 15 change +14% Gemfibrozil Group II: Baseline 46 ± 12 12 wks 50 ± 14 change +9%	Lovastatin Group I: Baseline 132 ± 58 12 wks 110 ± 49 change -17% Lovastatin Group II: Baseline 147 ± 76 12 wks 120 ± 73 change -19% Gemfibrozil Group I: Baseline 130 ± 48 12 wks 92 ± 47 change -28% Gemfibrozil Group II: Baseline 169 ± 71 12 wks 113 ± 70 change -33%	Lovastatin significantly more effective than gemfibrozil at reducing total cholesterol, LDL (p<0.001) and HDL (p<0.05) in groups I & II, and triglycerides in groups I (p<0.01) & II (p<0.001) .

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
Van Dam et al, 2001	Simvastatin 10 mg/day (n= 237) Fluvastatin 20 mg/day (n= 241) Initial dose doubled after 6 & 12 wks if LDL > than goal Pts whose dose was titrated up: Sim 64% vs Fluv 87%	mmol/L	Simvastatin: Baseline 6.8 ± 0.7 18 wks no data change -27% Fluvastatin: Baseline 6.8 ± 0.8 18 wks no data change -20%	Simvastatin: Baseline 4.7 ± 0.6 18 wks no data change -36% Fluvastatin: Baseline 4.7 ± 0.6 18 wks no data change -28%	Simvastatin: Baseline 1.1 ± 0.3 18 wks no data change +10% Fluvastatin: Baseline 1.2 ± 0.3 18 wks no data change +7%	Simvastatin: Baseline 1.9 ± 0.9 18 wks no data change -18% Fluvastatin: Baseline 2.0 ± 0.9 18 wks no data change -11%	Simvastatin significantly better at changing total cholesterol, triglycerides, HDL & LDL than fluvastatin (p<0.001)
Waters et al, 1994	Lovastatin 20 mg Evening (n= 165) Placebo Evening (n= 166) Dose doubled if LDL >130 mg/dL at wk 4 & again to 40 mg twice daily at wk 16. Dose reduced if LDL fell below 80 mg/dL Doses taken: 20 mg 91/165 40 mg 41/165 80 mg 33/165 Mean daily dose 36 mg	md/dL	Lovastatin: Baseline 250 no SD 24 mths no data change -21% ± 11 Placebo: Baseline 249 no SD 24 mths no data change -1.4% ± 9	Lovastatin: Baseline 173 no SD 24 mths no data change -29% ± 11 Placebo: Baseline 173 no SD 24 mths no data change -1.6 ± 12	Lovastatin: Baseline 41.3 no SD 24 mths 43.2 no SD change +7.3% ± 19 Placebo: Baseline 41.3 no SD 24 mths 42.0 no SD change +3.0% ± 16	Lovastatin: Baseline 194 no SD 24 mths no data change -8.1% ± 34 Placebo: Baseline 196 no SD 24 mths no data change +3.8% ± 36	Lovastatin significantly better at reducing total & LDL cholesterol than placebo (p<0.01)
Weir et al, 1996	Lovastatin 40 mg (n= 211) Evening meal Pravastatin 40 mg (n= 215) Bedtime	mg/dL	Lovastatin: Baseline 270 ± 33 12 wks 215 ± no SD change -20% ± 11 Pravastatin: Baseline 280 ± 35 12 wks 225 ± no SD change -19% ± 11	Lovastatin: Baseline 195 ± 30 12 wks 139 ± no SD change -28% ± 13 Pravastatin: Baseline 202 ± 30 12 wks 150 ± no SD change -26% ± 14	Lovastatin: Baseline 42 ± 10 12 wks 45 ± no SD change +8.5% ± 16 Pravastatin: Baseline 42 ± 10 12 wks 45 ± no SD change +8.2% ± 16	Lovastatin: Baseline 174 ±88 12 wks 153 ± no SD change -6.0% ± 38 Pravastatin: Baseline 183 ± 49 12 wks 157 ± no SD change -8.6% ± 55	All changes were significantly different from baseline

Author 2	Treatments & daily dose (mg)	Units	Total cholesterol	LDL cholesterol	HDL cholesterol	Triglycerides	Significance testing
West of Scotland Coronary Prevention Study Group, 1992	Pravastatin 40 mg daily (n=3302) Placebo (n=3293) Once daily evening	mg/dL	Pravastatin: Baseline 272 ±23 5 yrs PP analysis 218 change -20% Placebo: Baseline 272 ±22 5 yrs no significant change no significant change	Pravastatin: Baseline 192 ±17 5 yrs PP analysis 142 change -26% Placebo: Baseline 192 ±17 5 yrs no significant change no significant change	Pravastatin: Baseline 44 ±9 5 yrs PP analysis no data change +5% Placebo: Baseline 44 ±10 5 yrs no significant change no significant change	Pravastatin: Baseline 162 ±70 5 yrs PP analysis no data change -12% Placebo: Baseline 164 ±68 5 yrs no significant change no significant change	No data
Wiklund et al, 1993	Pravastatin 40 mg once in the evening (n= 71)	mmol/L	Pravastatin: Baseline 7.1 ± 0.13 12 wks 5.44 ± 0.11 change -26% no SD Gemfibrozil: Baseline 7.3 ± 0.14 12 wks 6.2 ± 0.12 change -15% no SD Placebo: Baseline 7.2 ± 0.12 12 wks 7.1 ± 0.12 change -1.7% no SD	Pravastatin: Baseline 5.2 ± 0.14 12 wks 3.4 ± 0.11 change -33% no SD Gemfibrozil: Baseline 5.2 ± 0.13 12 wks 4.3 ± 0.11 change -17% no SD Placebo: Baseline 5.1 ± 0.12 12 wks 5.0 ± 0.13 change -1.9% no SD	Pravastatin: Baseline 1.25 ± 0.05 12 wks 1.32 ± 0.04 change 5.93% no SD Gemfibrozil: Baseline 1.20 ± 0.05 12 wks 1.39 ± 0.04 change 15.21% no SD Placebo: Baseline 1.20 ± 0.04 12 wks 1.16 ± 0.03 change -4.4% no SD	Pravastatin: Baseline 1.8 ± 0.1 12 wks 1.5 ± 0.1 change -14% no SD Gemfibrozil: Baseline 1.8 ± 0.1 12 wks 1.0 ± 0.05 change -42% no SD Placebo: Baseline 1.8 ± 0.1 12 wks 1.8 ± 0.1 change +1.9% no SD	Significant change from baseline for all active treatments for all lipid parameters. Pravastatin significantly better at changing total cholesterol & LDL compared with gemfibraozil, placebo & baseline ($p<0.01$). Gemfibraozil, significantly better at changing triglycerides & HDL than compared with pravastatin , placebo & baseline ($p<0.01$).